The Loss Of ATRX Creates Susceptibility To KRAS-Mediated Pancreatic Damage by Young, Claire C
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-26-2017 12:00 AM 
The Loss Of ATRX Creates Susceptibility To KRAS-Mediated 
Pancreatic Damage 
Claire C. Young 
The University of Western Ontario 
Supervisor 
Dr. Christopher Pin 
The University of Western Ontario 
Graduate Program in Physiology and Pharmacology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Claire C. Young 2017 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cancer Biology Commons 
Recommended Citation 
Young, Claire C., "The Loss Of ATRX Creates Susceptibility To KRAS-Mediated Pancreatic Damage" 
(2017). Electronic Thesis and Dissertation Repository. 4654. 
https://ir.lib.uwo.ca/etd/4654 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
 i 
Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a five-year survival 
rate of 8%. Oncogenic KRAS mutation is found in greater than 95% of PDAC cases, but 
additional mutations or injury are required for disease initiation and progression. 
Chromatin remodeling protein ATRX has been previously implicated in DNA repair, 
replication and maintaining genomic stability. I hypothesized that loss of ATRX could 
increase the susceptibility of pancreatic tissue to pancreatic injury or KRAS-mediated 
damage. In this study, combination of inducible ATRX loss in adult mice with recurrent 
pancreatic injury or oncogenic KRAS activation resulted in increased pancreatic damage, 
including fibrosis, inflammation and acinar-to-ductal metaplasia. Interestingly, this effect 
was gender-specific, causing pancreatic damage exclusively in female mice with ATRX 
loss/KRAS activation. This study defines a novel role for ATRX within the exocrine 
pancreas, and provides insight into the epigenetic factors that can influence susceptibility 
to pancreatic disease.   
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Chapter 1  
1 Introduction 
 
The pancreas is an organ of endodermal origin, which develops from the embryonic 
foregut (Jørgensen et al., 2007). The pancreas is divided into two functional 
compartments; the endocrine portion and the exocrine portion. The endocrine portion 
comprises approximately 1-2% of total pancreatic mass, acts to regulate glucose 
homeostasis and consists of cell clusters called islets of Langerhans (Murtaugh and 
Melton et al., 2003). There are five types of endocrine cells present with pancreatic islets 
- b-cells, a-cells, d cells, PP cell and e cells, which produce the hormones insulin, 
glucagon, somatostatin, pancreatic polypeptide and ghrelin respectively (Murtaugh and 
Melton, 2003; Gittes, 2009).  
 
The exocrine portion of the pancreas, comprising the other 98-99% of total pancreatic 
mass, is responsible for the production and secretion of digestive enzymes to aid in the 
digestion and absorption of food (Shih et al., 2013). Cell types within the exocrine 
pancreas include pancreatic acinar cells, stellate cells, centroacinar cells and ductal cells 
(Cleveland et al., 2012). The functional unit of the exocrine pancreas are the pancreatic 
acinar cells, which are grouped into acini and have well-established basal-luminal 
polarity (Shih et al., 2013; Figure 1.1). Centroacinar cells are located in the transitional 
region between acinar cells and the ductal epithelium, which forms increasingly larger 
ductal structures before joining with the common bile duct (Cleveland et al., 2012). 
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Acinar cells produce and store zymogen granules containing inactive digestive enzymes. 
Following food ingestion, acinar cells are stimulated by cholecystokinin to exocytose 
their zymogen granules into adjacent pancreatic ducts. These granules move through the 
pancreatic ductal system and eventually drain into the duodenum of the small intestine to 
become active and assist in digestion (Shih et al., 2013). This thesis will focus on factors 
within the pancreatic acinar cell that increase susceptibility to diseases of the exocrine 
pancreas, including pancreatitis and pancreatic ductal adenocarcinoma (PDAC).  
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Figure 1.1. Schematic of major cell types within the exocrine pancreas. Acinar cells 
are organized into acini, surrounding a central duct composed of pancreatic duct cells. 
Pancreatic stellate cells are located in the peri-acinar space, while centroacinar cells are 
located in the transitional region between acinar and duct cells. Each acinar cell produces 
and stores zymogen granules containing inactive digestive enzymes.  
 
 
 
Acinus
Zymogen granules
Centroacinar cell
Duct cell
Acinar cell
Pancreatic stellate cell
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1.1 Pancreatitis  
 
Pancreatitis is an inflammatory disease predominantly thought to be caused by premature 
activation of digestive enzymes, particularly trypsin, within the pancreatic acinar cell 
leading to auto-digestion and tissue necrosis (Grady et al., 1998; Halangk et al., 2000; 
Murtaugh and Keefe, 2015). However, studies have suggested a more complex etiology 
for pancreatitis, as deletion of the trypsinogen gene in mice did not reduce pancreatitis-
associated inflammation (Dawra et al., 2011), and activation of NF-kB signaling alone 
was shown to be sufficient to induce acute pancreatitis (Baumann et al., 2007). This 
suggests multiple pathways could be working in parallel to cause pancreatitis. The two 
main types of pancreatitis are acute and chronic pancreatitis. While most cases of acute 
pancreatitis are mild, there is significant morbidity and mortality associated with a subset 
of severe acute pancreatitis cases (Koutroumpakis et al., 2017; Hazra et al., 2014). 
Approximately 70-80% of acute cases have an attributable cause, which include alcohol 
abuse, gall-stones, smoking, obesity and drug-hypersensitivity (Yadav et al., 2009; 
Badalov et al., 2007; Chen et al., 2012; Lerch and Aghdassi, 2010; Guda et al., 2011). 
Genetic factors play a role in pancreatitis; hereditary pancreatitis can be caused by 
mutations in the human cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal 
type 1 (SPINK1) genes (Teich et al., 2006; Witt et al., 2000), leading to premature 
enzyme activation within the pancreatic acinar cell. Additionally, mutations in 
chymotrypsin C (CTRC; Rosendahl et al., 2008) can lead to increased levels of active 
trypsin enzyme, while mutations in carboxypeptidase A1 (CPA1; Witt et al., 2013) are 
theorized to cause ER stress and are linked to pancreatitis. Lastly, mutations in the cystic 
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fibrosis transmembrane conductance regulator (CFTR) gene (Bishop et al., 2005; Sharer 
et al., 1998) can impair bicarbonate conductance and increase susceptibility to 
pancreatitis. Hereditary forms of pancreatitis have an earlier onset and present initially as 
acute episodes, before progressing to chronic pancreatitis (Howes et al., 2004; Girard et 
al., 1981). Further, multiple episodes of acute pancreatitis (recurrent acute pancreatitis) 
can be a risk factor for progression into chronic pancreatitis, especially in cases related to 
alcohol or smoking (Lankisch et al., 2009; Sankaran et al., 2015).   
 
Acute episodes of pancreatitis result in reversible damage to the pancreas which may be 
resolved within approximately one week (Koutroumpakis et al., 2017). Conversely, 
chronic pancreatitis (CP) is a progressive, long-term disease which can lead to 
irreversible damage to the pancreas (Kloppel et al., 1993; Amman et al., 1996). CP is 
characterized by an extensive inflammatory response, fibrosis and eventual endocrine and 
exocrine insufficiency as the disease progresses (Kloppel et al., 1993; Amman et al., 
1996; Malka et al., 2000). The leading cause for CP includes alcoholism (Nikkola et al., 
2017; Irving et al., 2009) and biliary-related etiologies (Bertilsson et al., 2015; van Baal 
et al., 2012), while smoking (Andriulli et al., 2010) can also play a role. There are 
approximately 14,400 Canadians currently living with CP, and it is expected that more 
than 2,000 new cases will be diagnosed each year (Teshima et al., 2012). Patients with 
CP have a greatly reduced quality of life, with many patients becoming unemployed or 
retiring earlier than planned due to decreased physical, social and/or emotional wellbeing 
(Wehler et al., 2003). Diabetes mellitus is a common co-morbidity with CP; 20 years 
after onset approximately 46% of chronic pancreatitis patients have been diagnosed with 
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secondary diabetes (Type 3c diabetes mellitus) (Pan et al., 2016). Further, significant 
mortality is associated with CP, with one long-term study identifying 44% mortality 
within 10 years post-diagnosis (Yadav et al., 2011).  
 
1.1.1 Animal models of pancreatitis  
 
Animal models utilized to replicate acute human pancreatic injury includes hormonally-
induced pancreatitis (e.g. cerulein), administration of basic amino acids (L-arginine), 
diet-induced pancreatitis (choline-deficient diet enriched with ethionine) and pancreatic 
duct ligation (Lampel et al., 1977; Tani et al., 1987; Tani et al., 1990; Gilliland et al., 
1980; Mooren et al., 2003). The most commonly-used model is cerulein-induced 
pancreatitis (CIP), in which supraphysiological doses of cerulein, a cholecystokinin 
analogue, blocks enzyme secretion and leads to intracellular enzyme activation (Saluja et 
al., 1999). Treatment with cerulein can be administered over a short time period (4-7 
injections in one day), to mimic acute pancreatitis, or extended over a few weeks to 
replicate the phenotype of recurrent pancreatitis (Elsasser et al., 1992). However, unlike 
CP in humans, mouse pancreas regenerates following recurrent pancreatitis, reversing the 
pancreatic damage (Elssasser et al., 1992). Long-term cerulein injections are still utilized 
as a model of CP, as it recapitulates characteristics of the disease including extensive 
fibrosis (Neuschwander-Tetri et al., 2000). This damage can be further amplified by 
combination of cerulein with an additional sensitizer, such as ethanol (Deng et al., 2005) 
or pancreatic duct ligation (Miyauchi et al., 2007).  
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As a result of studies using animal pancreatic injury models, the progression of 
pancreatitis has been characterized. Induction of pancreatic injury results in dysfunctional 
calcium signaling with premature zymogen activation in acinar cells and activation of 
inflammatory responses through release of TNF-a and the NF-kB pathway that can 
further amplify enzyme activation (Krüger et al., 2000; Mooren et al., 2003; Sendler et 
al., 2013; Dawra et al., 2011; Abdulla et al., 2011). Widespread apoptosis, necrosis and 
edema is observed (Dawra et al., 2011). Acinar cell damage leads to the release of 
chemokines and cytokines (including monocyte chemotactic protein, cytokine-induced 
neutrophil chemoattractant, interleukin-6 (IL-6)) which can enhance pancreatic 
inflammation and attract infiltrating immune cells, including neutrophils and 
macrophages (Brady et al., 2002; Shimada et al., 2002). Accordingly, blocking 
interleukin-6 (IL-6) or chemokine receptor CXCR2 attenuates inflammation in 
pancreatitis models (Chao et al., 2006; Steele et al., 2015). 
 
In CP, recurrent injury and inflammation promotes fibrosis, which is mediated through 
activation of quiescent pancreatic stellate cells (PSCs) (Schneider et al., 2001; Mews et 
al., 2002). Macrophages present in CP have been shown to secrete factors that promote 
PSC-mediated fibrosis (Treiber et al., 2011). Further, PSCs can be activated by cytokines 
that are shown to be upregulated in acute pancreatitis (including TNF-a and IL-6), and 
TGF-b signaling can promote this process (Mews et al., 2002; van Laethem et al., 1996). 
Once activated, PSCs can secrete extracellular matrix components, primarily collagen, 
that contribute to fibrosis (Neushwander-Tetri et al., 2000).  
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1.1.2 Regeneration & Acinar to ductal metaplasia (ADM) 
 
Pancreatic damage from acute pancreatitis appears to subside within 1-2 weeks following 
an episode of acute pancreatitis, indicating the regenerative capability of acinar tissue 
(Siveke et al., 2008; Fendrich et al., 2009). A major event in the pancreatic response to 
injury is acinar to ductal metaplasia (ADM), in which mature acinar cell markers (Mist1, 
Amylase) are downregulated in acinar cells, while markers typically expressed in 
pancreatic progenitor cells (sex-determining region Y box 9 (Sox9), pancreatic and 
duodenal homeobox 1 (Pdx1), hepatocyte nuclear factor 6 (Hnf6)) or duct cells (keratin 
19 (Ck19)) are upregulated (Karki et al., 2015; Pinho et al., 2011; Prevot et al., 2012; 
Figure 1.2). This event could indicate trans-differentiation from acinar to duct cell, or 
rather dedifferentiation of acinar cells to a progenitor-like state. ADM can be important 
for regeneration, but the prolonged presence of ADM may sustain a loss of acinar identity 
and provide susceptibility for oncogenic transformation (Halbrook et al., 2017; Shi et al., 
2013; Kopp et al., 2012). Several key factors have been identified that establish or 
maintain acinar cell identity, including pancreas specific transcription factor, 1a (Ptf1a), 
GATA-binding factor 6 (Gata6), nuclear receptor subfamily 5a2 (Nr5a2) and Mist1 
(Hoang et al., 2016; Martinelli et al., 2013; von Figura et al., 2014b; Johnson et al., 
2004). Accordingly, loss of Nr5a2 or Mist1 increases susceptibility to pancreatic damage 
and decreases the regenerative capability of tissue following injury (von Figura et al., 
2014b; Kowalik et al., 2007). Factors involved in mature acinar cell organization 
(connexin 32 (Cx32), heat shock protein 27 (Hsp27)) can also influence response to 
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pancreatic injury by altering acinar cell-cell communication and the acinar cell 
cytoskeleton (Frossard et al., 2003; Kubisch et al., 2004).  
 
Many signaling pathways required for ADM and subsequent pancreatic regeneration have 
been identified, including epidermal growth factor receptor (EGFR) and downstream 
KRAS activation of MEK/ERK signaling (Shi et al., 2013; Halbrook et al., 2017). 
Overexpression of EGF is sufficient to drive ADM in a mouse model (Means et al., 
2003), and high levels of EGF ligands, including transforming growth factor a (TGF-a) 
and amphiregulin (AREG), or EGFR have been observed in CP (Ardito et al., 2012). 
Downstream of EGFR, inhibition of MEK signaling in a mouse model of CP was 
sufficient to block ADM (Halbrook et al., 2017), supporting the requirement for EGFR 
and MEK/ERK signaling in the occurrence of ADM.  
 
Notch, Wnt and Hedgehog signaling all play a role in acinar regeneration following 
injury, by regulating the differentiation status of acinar cells post-injury (Morris et al., 
2010a; Morris et al., 2010b; Siveke et al., 2008; Fendrich et al., 2009). Chromatin 
remodeling proteins such as Enhancer of Zeste 2 (EZH2; Mallen St. Clair et al., 2012) 
and B-cell specific Moloney murine leukemia virus insertion site 1 (BMI1; Fukuda et al., 
2012) are important in pancreatic regeneration, promoting a proliferative state. Many of 
the pathways involved in pancreatic regeneration are also upregulated in pancreatic 
cancer (including Kras, Wnt and Notch signaling) (Bailey et al., 2016). Accordingly, CP 
is a risk factor for pancreatic cancer (Lowenfels et al., 1993; Raimondi et al., 2010). The 
 10 
relative risk for the development of pancreatic cancer in chronic pancreatitis is 13.3-fold, 
with increased risk (69-fold) for those with hereditary pancreatitis (Raimondi et al., 
2010). Identification of pathways or events that link CP to pancreatic cancer would be 
beneficial in limiting the progression of pancreatic disease.  
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Figure 1.2. Schematic of acinar-to-ductal metaplasia (ADM). In response to 
pancreatic injury, acinar cells can undergo a process involving upregulation of pancreatic 
progenitor (PDX1, SOX9, HNF6) and ductal markers (CK19) and decreased in mature 
acinar cell markers (MIST1, Amylase, Carboxypeptidase), progressing towards a duct 
cell phenotype. 
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1.2 Pancreatic Ductal Adenocarcinoma (PDAC) 
 
Pancreatic cancer is a relatively rare but lethal disease, accounting for approximately 
2.5% of new cancer cases in Canada last year, while causing 6% of cancer-related deaths 
(Canadian Cancer Statistics, 2016). The most common type of pancreatic cancer is 
pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 85% of total 
pancreatic cancer cases (Ryan et al., 2014). Currently, the five-year survival rate for 
PDAC is approximately 8% (Pancreatic Cancer Facts, 2016) because PDAC is typically 
diagnosed in the late stages due to lack of early symptoms and biomarkers, and current 
treatments are limited. Less than 20% of cases are treated surgically, as this treatment 
option is typically reserved for cases that have not yet metastasized (Pancreatic Cancer 
Facts, 2016). Available chemotherapeutic agents include a standard first-line treatment 
gemcitabine (median survival 6.8 months), along with FOLFIRINOX, a combinatorial 
treatment which leads to slight improvement in survival (median survival 11.1 months; 
Conroy et al., 2011). Both treatments have limited efficacy long-term (Conroy et al., 
2011). One of the difficulties in treating PDAC is the presence of a dense stroma that 
may support tumour progression and block effective treatments, consisting of a 
heterogeneous population of cells including fibroblasts, pancreatic stellate cells and 
inflammatory cells, and extra-cellular matrix (ECM) components (Neesse et al., 2015; 
Hwang et al., 2009; Mahadevan et al., 2007). 
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The etiology behind the majority of PDAC cases is unknown, with hereditary factors 
accounting for approximately 10% of PDAC cases (Ryan et al., 2014). Families with a 
history of pancreatic cancer are at higher risk, although the onset of familial pancreatic 
cancer occurs only 5 years earlier than the average pancreatic cancer age of diagnosis 
(Peterson et al., 2015). Genetic causes to account for increased familial risk have only 
been identified in a subset of cases, including hereditary syndromes such as familial 
breast cancer (BRCA2), Lynch syndrome and Peutz Jeghers syndrome (Klein et al., 
2004; Shi et al., 2009; Peterson et al., 2015; Matsubayashi et al., 2017). Patients with 
mutation in the p16 gene (linked to familial atypical mole melanoma) have 17% 
increased risk of developing pancreatic cancer, and mutations in the palladin gene, 
encoding a protein involved in cytoskeletal organization, have been shown to play a role 
in familial pancreatic cancer (Pogue-Geile et al., 2006). Aside from genetic factors, 
lifestyle has been implicated in the etiology of pancreatic cancer, with proposed links to 
cigarette smoking, high alcohol intake and increased body mass (Bosetti et al., 2012; 
Wang et al., 2016; Aune et al., 2012).  
 
1.2.1 Origin & acquired mutations in PDAC 
 
One of the major controversies regarding pancreatic cancer is the cell of origin from 
which PDAC arises. Precursor lesions for PDAC include pancreatic intraepithelial 
neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMN) and mucinous 
cystic neoplasms (MCNs; Hruban et al., 2007). Although PDAC demonstrates ductal 
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characteristics, and these three precursor lesion types express ductal markers, lineage 
tracing experiments in mouse models strongly support acinar cells as the cell of origin for 
most PDAC cases (Kopp et al., 2012; Zhu et al., 2007; Ji et al., 2009; De La O et al., 
2008; Morris et al,. 2010b). These experiments demonstrated the capability of acinar cells 
to transdifferentiate into duct cells, in both mouse models and cultured human acinar cells 
(Strobel et al., 2007; Houbracken et al., 2011), and acinar cells can contribute to PanIN 
lesions (Kopp et al., 2012). PanINs are non-invasive, neoplastic precursor lesions which 
progress from low-grade PanIN1 to PanIN3, before reaching full-blown PDAC (Hruban 
et al., 2004). PanIN1 lesions can accumulate over time and can be found in non-
malignant pancreata, while PanIN3 lesions are more typically associated with the 
occurrence of invasive PDAC (Andea et al., 2003; Hruban et al., 2004).  
 
A series of acquired mutations occurs as PDAC develops from its precursor lesions. The 
earliest mutation is believed to occur in the KRAS gene, due to its presence in over 95% 
of PDAC cases (Morris et al., 2010b), and activating KRAS mutation are observed in over 
90% of early-grade PanIN1 lesions (Kanda et al., 2012). Other common early mutations 
which increase in frequency throughout PDAC progression include CDKN2A (encoding 
p16INK4A/p19ARF), TP53, and SMAD4, which are linked to cell cycle regulation, DNA 
damage control and TGF-b signaling (Makohan-Moore et al., 2016; Waddell et al., 2015; 
Jones et al., 2008). However, PDAC is a genetically heterogeneous disease, and genomic 
sequencing has revealed additional mutations that occur at a lower frequency in subsets 
of PDAC (Jones et al., 2008; Bailey et al., 2016). An extensive study by Bailey et al., 
2016 used these mutations to identify 10 common signaling pathways that may be 
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mutated in PDAC, and classified PDAC into four subtypes accordingly. These pathways 
included mutation in Notch signaling, SWI/SNF complexes, chromatin modifications and 
DNA repair. PDAC is also characterized by large variations in chromosomal structure. 
Waddell et al., (2015) demonstrated the presence of significant chromosomal 
rearrangements and alterations which could disrupt gene expression in PDAC. The wide 
range of acquired mutations and chromosomal instability in PDAC indicates the 
importance of maintaining genomic stability to prevent PDAC initiation and progression.  
 
1.3 KRAS 
 
1.3.1 KRAS gene & protein 
 
It has been estimated that approximately 30% of all cancers contain an activating RAS 
mutation (Fernandez-Medarde et al., 2011). Within the specific RAS family, there are 
three different classes of GTPases: HRAS, NRAS and KRAS. The members of the RAS 
protein superfamily contain GTPase activity, and share a common catalytic G domain 
with variability in their cellular processes and function (Paduch et al., 2001). Each RAS 
protein (HRAS, NRAS, KRAS) is implicated in different cancer types, with KRAS 
mutations found most frequently in epithelial tumours including lung, colon and 
pancreas, as well as biliary tract, endometrial and ovarian cancers among others (Jančik 
et al., 2010; Sohal et al., 2016; Schubbert et al., 2007). Pancreatic adenocarcinomas have 
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the highest rate of oncogenic KRAS mutation, with over 95% of cases carrying mutations 
(Morris et al., 2010b).  
 
The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is located on the short arm 
of chromosome 12, and has two different isoforms; KRAS4A and KRAS4B due to 
alternative splicing of exon 4. KRAS4B is more predominantly expressed in most human 
cells (Jančik et al., 2010), and the majority of studies involving the KRAS protein focus 
on the protein encoded by this isoform. The KRAS protein is a small 21kDa GTPase, 
activated via GTP-binding and inactive when bound to GDP (Jančik et al., 2010). The 
switch between active and inactive KRAS is mediated by two proteins, a guanine 
nucleotide exchange factor (GEF) which promotes GTP binding, and a GTPase activating 
protein (GAP) which promotes GTP hydrolysis (Jančik et al., 2010). Activating KRAS 
mutations impede the ability of GAPs to induce GTP hydrolysis, maintaining KRAS in 
an active state (Trahey et al., 1987). The most common amino acids for mutation include 
residues G12, G13 and Q61 (Buhrman et al., 2010; Scheffzek et al., 1997). Stimulation of 
KRAS activity by various growth factors or cytokines activates downstream signaling 
pathways, regulating cellular processes including cell survival, proliferation and 
differentiation (Crespo et al., 2000; Matallanas et al., 2006). External stimuli of KRAS 
activity include inflammatory signals, as well as GPCR-mediated activation, including 
EGFR signaling, through binding of EGFR ligands such as EGF and TGFa (Daniluk et 
al., 2012; Harris et al., 2003; Logsdon et al., 2016). 
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1.3.2 Downstream pathways of KRAS 
 
Activation of oncogenic KRAS, and subsequent downstream signaling pathways, is an 
important driving factor in PDAC initiation and progression (Collisson et al., 2012). The 
canonical downstream target of KRAS is mitogen-activated protein kinase (MAPK) 
signaling (Figure 1.3), in which the KRAS protein binds to serine/threonine kinase RAF 
(MAPKKK), inducing translocation of the protein to the plasma membrane where it is 
phosphorylated (Votjek et al., 1993; Marais et al., 1995). Active RAF then 
phosphorylates MEK (MAPKK), which can then phosphorylate and activate downstream 
proteins ERK1/2 (MAPK1/2; Crespo et al., 2000). Once phosphorylated, ERK proteins 
can translocate to the nucleus and target a variety of downstream effectors, including 
transcription factors such as JUN and ELK1 to regulate gene expression and cellular 
proliferation levels (Crespo et al., 2000; Schubbert et al., 2007).  
 
However, KRAS signaling is diverse and context-dependent, and influences many 
downstream signaling pathways apart from MAPK signaling. Two major pathways 
activated by KRAS are the phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-
dependent protein kinase 1 (PDK1)-Akt pathway and the RalGDS/p38 MAPK pathway. 
The PI3K pathway is a well-characterized Ras-effector pathway known to mediate cell 
survival (Castellano and Downward, 2011). Activation of PI3K leads to production of the 
substrate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), that binds and activates PDK1 
and Akt/PKB and lead to a series of downstream phosphorylation events (Castellano and 
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Downward, 2011; Eser et al., 2013). In addition, KRAS activates exchange factors for 
Ral GTPases (including Ral-GDS), leading to subsequent activation of Ral and 
downstream phospholipase D (PLD; Lim et al., 2005). Other KRAS-mediated pathways 
include RAC and RHO, and PLCe pathways (Schubbert et al., 2007; Eser et al., 2014; 
Pylayeva-Gupta et al., 2011). Ras-regulation of Rho-GTPases has been demonstrated to 
influence cytoskeleton regulation (Chen et al., 2003; Sahai et al., 2001), while Ras-
mediated PLCe signaling can activate protein kinase C (PKC) and regulate calcium 
signaling (Song et al., 2001).  
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Figure 1.3. MAPK signaling pathway downstream of active KRAS. Once activated 
(by various stimuli including EGFR signaling), the KRAS GTPase induces a series of 
phosphorylation events. Active KRAS phosphorylates RAF (mitogen activated protein 
kinase kinase kinase; MAPKKK), which phosphorylates MEK (mitogen activated protein 
kinase kinase; MAPKK) with subsequent phosphorylation of ERK (mitogen activated 
protein kinase; MAPK). Phosphorylated ERK can translocate into the nucleus and target 
specific transcription factors to alter gene expression and influence cellular proliferation. 
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1.3.3 KRAS mutations in PDAC 
 
The MAPK pathway activated by KRAS is vital in driving oncogenic PDAC (Collisson 
et al., 2012; Collins et al., 2014), and studies demonstrate activation of endogenous or 
transgenic oncogenic KRAS (KRASG12V or KRASG12D) in early pancreas leads to the 
formation of PanINs and PDAC (Tuveson et al., 2004; Guerra et al., 2007; Grippo et al., 
2003; Hingorani et al., 2003). Furthermore, the use of models in which KRAS activity 
can be turned on/off demonstrate the requirement of KRAS for both the initiation and 
maintenance of PDAC (Collins et al., 2012). However, adult acinar tissue is less 
susceptible than the developing pancreas to the induction of oncogenic KRAS (Huang et 
al., 2014; Ji et al., 2009; Morris et al., 2010b), and additional factors such as injury or 
acquired mutation are required to promote PanIN formation.  
 
Daniluk et al., (2012) demonstrated that inflammatory stimuli in mice with oncogenic 
KRASG12D lead to PanINs and a chronic inflammatory response, as opposed to minimal 
effects from the same stimuli in wild-type mice. Furthermore, activation of 
inflammatory-associated factor NFATc1and STAT3 co-operates with KRASG12D to 
promote pancreatic cancer (Baumgart et al., 2014). This provides evidence to suggest 
oncogenic KRAS makes acinar tissue more susceptible to the activation of inflammatory 
pathways. Accordingly, the combination of KRAS mutation with pancreatic injury 
greatly increases the amount of pancreatic damage. As opposed to wild-type mouse 
models, mice with oncogenic KRAS activation that undergo acute pancreatic injury do 
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not recover to the same extent, and form PanIN lesions (Collins et al., 2012; Morris et al., 
2010a). Acute pancreatitis accelerated the onset of PDAC in mice with KRASG12D 
(Carriere et al., 2011), and induction of CP in KRASG12D mice was sufficient to promote 
PDAC formation (Guerra et al., 2007). These studies demonstrate a co-operative role for 
oncogenic KRAS activation and pancreatic injury in the occurrence of PDAC.  
 
Oncogenic KRAS activation also promotes PDAC with loss of function in known tumour 
suppressor genes, including p16Ink4a/p19Arf, Trp53 and Dpc/Smad4 (Bardeesy et al., 2006; 
Hingorani et al., 2005; Kojima et al., 2007; Izeradjene et al., 2007). Furthermore, 
combination of KRASG12D with loss of mature acinar cell factors such as Mist1, Nr5a2 
and Gata6 promotes PanIN formation (Shi et al., 2013; von Figura et al., 2014b; 
Martinelli et al., 2015). KRASG12D combined with upregulation of pathways associated 
with a developmental or progenitor pancreatic phenotype, including Notch and Hippo 
signaling, also promote PanIN formation (De La O et al., 2008; Zhang et al., 2014), 
suggesting maintenance of acinar cell differentiation constrains KRAS-mediated 
pancreatic disease. Lastly, oncogenic KRAS signaling can cooperate with the presence or 
loss of chromatin remodeling proteins to promote PDAC, including members of the 
polycomb protein family BMI1 and EZH2 (Bednar et al., 2015; Mallen-St. Clair et al., 
2012), as well as SWI/SNF chromatin remodeling protein BRG1 (von Figura et al., 
2014a).  
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1.4 Chromatin Modifications & SWI/SNF Chromatin 
Remodelers 
 
1.4.1 Chromatin structure & modification 
 
Modifications to chromatin can alter genomic stability and gene expression patterns and, 
thus, there is increasing evidence for a role of chromatin remodelers in PDAC 
suppression (Bailey et al., 2016; Wadell et al., 2015). The packaging of histones and 
DNA into chromatin is an essential organization of genome, which regulates various 
DNA processes including transcription, replication and repair. Chromatin consists of 147 
DNA base pairs wrapped around an octamer of histone proteins (sets of histone variants 
H2A, H2B, H3 and H4) to form a nucleosome core, which are connected by sections of 
linker DNA (Luger et al., 1997; Richmond and Davey, 2003).  Histone structure involves 
basic N-terminal tails that protrude from the nucleosome unit, which undergo histone 
modifications including acetylation, methylation and phosphorylation (Bannister and 
Kouzarides, 2011; Luger at el., 1997). Histone tail acetylation is almost always associated 
with increased chromatin accessibility and transcription, and conversely, deacetylation is 
considered to be a mechanism of gene silencing (Kouzarides, 2007). Methylation 
modifications are more specific to a particular arginine or lysine on a histone tail, can 
occur as mono, di or trimethylation and, depending upon location, can be activating or 
repressive marks (Kouzarides, 2007). For example, trimethylation of lysine 4 on histone 
3 (H3K4me3) is shown to be an activating mark, while trimethylation of lysine 9 on 
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histone 3 (H3K9me3) is repressive (Schuettengruber et al., 2007; Margueron et al., 2011; 
Zhao et al., 2007).  
 
Histone modifications help regulate nucleosome structure and recruit chromatin 
remodeling enzymes dependent on the type of modification (Kouzarides, 2007). Once 
recruited, chromatin remodelers utilize their ATPase activity to incorporate specific 
histone variants, changing the accessibility and structure of the chromatin region 
(Bushbeck et al., 2017). Non-canonical histone variants (such as histone 3.3) are viewed 
as epigenetic marks that regulate genomic function, are synthesized throughout the cell 
cycle and are not dependent on replication for deposition (Buschbeck et al., 2017).  
 
1.4.2 SWI/SNF family of chromatin remodelers 
 
Chromatin remodelers that contain an ATPase subunit are divided into subgroups, 
including switching defective/sucrose non-fermenting (SWI/SNF), imitation switch 
(ISWI), chromodomain, helicase, DNA binding (CHD/Mi2), SWI/SNF-related adenosine 
triphosphate complex (SWRI) and inositol requiring 80 (INO80) ATPases, each with a 
distinct structure and ATPase (Wilson et al., 2011; Mohrmann et al., 2005). These groups 
utilize energy from ATP hydrolysis to rearrange chromatin structure by altering histone-
DNA interaction and sliding nucleosomes along DNA (Mohrmann et al., 2005; Vignali et 
al., 2000). The first SWI/SNF complex was characterized in yeast (Stern et al., 1984; 
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Neigeborn and Carlson, 1984), with homologous complexes identified in Drosophila and 
mammals (Papoulos et al., 1998; Wang et al., 1996). The SWI/SNF complexes are large 
and consist of 9-12 subunits (Smith et al., 2003; Wang et al., 1996), and the composition 
of proteins can vary. In humans, there are two ATPase subunits which can be 
incorporated: BRM(SMARCA2) or BRG1(SMARCA4) (Bultman et al., 2000; Wang et 
al., 1996).  
 
SWI/SNF complexes have many diverse regulatory roles in the genome, and mutations in 
SWI/SNF complexes have been found in a number of cancer types. A survey of 44 
exome/genome sequencing studies identified SWI/SNF subunits mutations in 19.6% of 
all human tumours (Kadoch et al., 2013). BRG1 mutations have been detected in lung 
cancer and multiple human cancer cell lines, including those lines derived from prostate, 
lung, breast and pancreas (Marquez-Vilendrer et al., 2016; Wong et al., 2000). Mutations 
in other subunits of SWI/SNF complexes have been correlated to cancer, including 
ARID1A in breast and clear cell ovarian cancers (Jones et al., 2011; Takao et al., 2017), 
and PBRM1, mutated in 41% of clear cell renal cancers (Varela et al., 2011). A study of 
esophageal squamous cell carcinomas demonstrated cases with inactivating mutation in 
ARID1A, BRG1 and ATRX among others, suggesting SWI/SNF mutation may be an early 
occurrence in this cancer type (Nakazato et al., 2010). This thesis will focus specifically 
on SWI/SNF chromatin remodelling protein ATRX, and investigate the potential role of 
ATRX loss in promoting pancreatic disease.  
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1.4.3 a-thalassemia/mental-retardation, X-linked protein (ATRX) 
syndrome 
 
The ATRX syndrome, which includes the unusual co-presentation of intellectual 
disability and a-thalassemia in male children from three unrelated families, was first 
defined in 1981 (Weatherall et al., 1981). Patients with ATRX syndrome present with a 
spectrum of clinical symptoms, including severe cognitive defects, facial abnormalities 
and a-thalassemia (Gibbons et al., 1995). Additional symptoms may include urogenital 
and skeletal abnormalities, generalized hypotonia from birth, short stature and 
gastrointestinal issues (Gibbons et al., 2000a). As an X-linked disorder, ATRX syndrome 
occurs predominantly in males. Phenotypically normal carrier females who are 
heterozygous for ATRX mutation show skewed X chromosome inactivation (XCI) for the 
X-chromosome carrying the mutation (Gibbons et al., 1992). Mutations in the ATRX gene 
causing ATRX syndrome are typically missense and lead to hypomorphic function of the 
ATRX protein (Gibbons et al., 2008). It appears that complete loss of ATRX function is 
lethal, as mouse models carrying germ-line null Atrx mutations/deletions do not produce 
viable embryos (Garrick et al., 2006). It was shown that Atrx deletion in the 8-16 cell 
stage of the mouse embryo caused defects in the formation of extraembryonic 
trophoblast, causing lethality within 9 days of Atrx ablation (Garrick et al., 2006). 
 
 
 
 26 
1.4.4 ATRX gene & protein structure 
 
The ATRX gene is 36 exons long, and spans approximately 300 kb on the X-chromosome 
(Picketts et al., 1996). There are two alternatively spliced transcripts of approximately 
10.5 kb, which are different at their 5' ends due to alternative splicing of exon 6 (Villard 
et al., 1997). ATRX is ubiquitously expressed in all tissue types, with high levels of 
expression in the brain (Gecz et al., 1994). The two isoforms of ATRX give rise to 
proteins of 265 kDa or 280 kDa. The ATRX protein belongs to the SNF2 subgroup of the 
SWI/SNF protein family (Picketts et al., 1996). It contains two functionally conserved 
domains; an N-terminus ADD (ATRX-DNMT3-DNMT3L) domain and a C-terminus 
SWI/SNF ATPase domain (Figure 1.4; Argentaro et al., 2007). The ADD domain is 
named based on its sequence homology with a family of de novo DNA 
methyltransferases, and is highly cysteine-rich with two different types of zinc finger 
motifs (Argentaro et al., 2007). The first motif is a zinc finger, and the second is an 
atypical plant homeodomain (PHD) zinc finger (Argentario et al., 2007; Gibbons et al., 
1997). The C-terminus of the ATRX protein contains a SWI/SNF ATPase domain with 
helicase activity involved in chromatin remodeling (Mitson et al., 2011). The presence of 
mutations leading to ATRX syndrome are most often found in one of these two 
conserved domains, with approximately 49% of ATRX syndrome mutations in the ADD 
domain, and 30% in the SWI/SNF ATPase domain, indicating the functional importance 
of each domain (Gibbons et al., 2008). There is also a conserved, truncated isoform of the 
ATRX protein called ATRXt, caused by a failure to splice exon 11 of the ATRX gene 
(Garrick et al., 2004). The resultant protein lacks the C-terminal SWI/SNF domain, 
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suggesting it has reduced functionality compared to the full-length ATRX protein 
(Garrick et al., 2004).  
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Figure 1.4. Schematic of ATRX protein. The ATRX protein contains two function 
domains; a N-terminal ADD (ATRX-DNMT3-DNMT3L) domain and a C-terminal 
SWI/SNF ATPase domain. Within the ADD domain, there are two zinc finger motifs; 
GATA-1like C2C2 and atypical plant homeodomain (PHD). Interaction sites between 
ATRX and death-domain associated protein (DAXX) or heterochromatin protein-1 (HP1) 
are indicated in pink. 
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1.4.5 Binding Partners & ATRX cellular localization 
 
ATRX is a nuclear protein, associated with the nuclear matrix during interphase (Berube 
et al., 2000). Nuclear localization of ATRX can be altered with ATRX mutation, leading 
to a more diffuse nuclear pattern of staining (Cardoso et al., 2000). During the metaphase 
stage of mitosis, ATRX localizes to condensed chromosomes following a 
phosphorylation event in association with heterochromatin protein-1 (HP1) (Berube et al., 
2000).  
 
The ability of ATRX to bind to DNA through its N-terminal domain was demonstrated in 
vitro (Cardoso et al., 2000), and it can interact with and bind RNA (Sarma et al., 2014). 
ATRX is often localized to areas of heterochromatin and largely repetitive regions of 
DNA, including telomeres and centromeres (McDowell et al., 1999; Law et al., 2010; 
Lewis et al., 2010). The localization of ATRX to heterochromatin is believed to be 
mediated through its N-terminal ADD domain (McDowell et al., 1999;), as well as the 
interaction between ATRX and HP1. The ADD domain binds to histone 3 (H3) tails with 
the specific histone trimethylation mark H3K9me3, a marker of heterochromatin, 
especially in the absence of H3K4 methylation (Dhayalan et al., 2011). HP1 is thought to 
stabilize this ATRX recruitment event, as mutation in the HP1 binding site on the ATRX 
protein reduces its heterochromatic localization (Figure 1.4; Eustermann et al., 2011). An 
additional interaction occurs specifically in neurons, where methyl-CpG binding protein 
(MECP2) associates with ATRX to recruit it to heterochromatin (Nan et al., 2007). 
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Importantly, the localization of ATRX is not solely confined to heterochromatic regions; 
ATRX can bind to intergenic regions and gene bodies, especially those containing 
tandem repeat sequences (Law et al., 2010).  
 
In addition to HP1, a major protein partner of ATRX is death domain-associated protein 
(DAXX). The DAXX protein was demonstrated using immunoprecipitation assays to be 
in complex with ATRX, and responsible for targeting ATRX to promyelocytic leukemia 
PML nuclear bodies (Xue et al., 2003; Tang et al., 2004). DAXX works in complex with 
ATRX to mediate incorporation of histone variant 3.3 (H3.3) at pericentric 
heterochromatin and telomeres in a replication-independent manner (Drane et al., 2010; 
Lewis et al., 2010). Once H3.3 is incorporated, it can be targeted for K9 trimethylation to 
produce a heterochromatic state and maintain stability of the telomere (Udugama et al., 
2015). 
 
1.4.6 Regulation of gene expression and DNA methylation 
 
Loss of ATRX leads to decreased expression of the a-globin gene cluster located on 
chromosome 16 (Wilkie et al., 1990), suggesting it may act as a transcriptional regulator. 
The interaction of ATRX with the Su(var)3-9, enhancer of zeste, and trithorax (SET) 
domain of the EZH2 protein, part of the Polycomb Repressive Complex 2 (PRC2), 
provides further evidence of a regulatory role for ATRX in gene expression (Cardoso et 
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al., 1998). PRC2 is a histone methylase complex, associated with gene silencing and 
repressive chromatin (Margueron and Reinberg, 2011). ATRX can recruit PRC2 to Xist 
RNA during X chromosome inactivation, as well as other PRC2 targets throughout 
genome (Sarma et al., 2014). ATRX also associates with the inactivated X-chromosome 
(Baumann and De La Fuente, 2009), and is required to maintain gene silencing at 
interstitial heterochromatin and imprinted regions (Voon and Wong, 2015; Kernohan et 
al., 2010). Finally, ATRX influences DNA methylation throughout the genome, as 
patients with ATRX syndrome show patterns of altered DNA methylation (Gibbons et al., 
2000b). DNA methylation analysis performed on blood samples of ATRX patients 
demonstrated differentially DNA methylated regions, including pericentromeric and 
telomeric regions in patients with ATRX mutation (Schenkel et al., 2017). Taken 
together, these studies strongly suggest a role for ATRX in altering gene expression. 
Further, ATRX regulates additional processes aside from gene regulation, including DNA 
replication, repair and cell cycle processes.  
 
1.4.7 Cell cycle regulation 
 
The effects of ATRX loss on mitosis in proliferating cells are evident in several different 
tissue types, including neuroprogenitor cells, Sertoli cells of the testes, skeletal muscle 
and forelimb mesenchyme (Bagheri-Fam et al., 2011; Bérubé et al., 2005; Huh et al., 
2012; Ritchie et al., 2008). ATRX knockdown in HeLa cells led to prolonged 
prometaphase to metaphase transition, due to impaired chromosome congression to the 
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spindle equator (Ritchie et al., 2008). ATRX knockdown reduced cohesion between sister 
chromatids, and caused chromosome segregation defects during mitosis (Ritchie et al., 
2008). Increased apoptosis was observed in Atrx-null mouse neuroprogenitor cells, 
cultured from E12.5 embryos containing a conditional neuroprogenitor-specific Atrx 
deletion, suggesting mitotic defects from ATRX loss may contribute to cell death in the 
developing forebrain (Berube et al., 2005; Ritchie et al., 2008; Seah et al., 2008). Cell 
cycle impairment was observed in skeletal muscle development, where ATRX loss led to 
delayed S phase progression and mitotic spindle defects in myoblasts (Huh et al., 2012), 
and in Atrx-null Sertoli cells of the testes, causing prolonged G2 to M phase transition and 
increased apoptosis (Bagheri-Fam et al., 2011). These studies demonstrate a role for 
ATRX in maintaining genomic stability in actively dividing cells. Interestingly, although 
Atrx deletion in the forelimb mesenchyme lead to brachydactyly and increased cell death 
(Soloman et al., 2013b), loss of ATRX in chondrocytes or osteoblasts had minimal 
effects on cartilage and skeletal development (Soloman et al., 2013a; Soloman et al., 
2013b). Within the exocrine pancreas, the role of ATRX in pancreatic development has 
not yet been characterized. ATRX has also been implicated in regulating meiosis, as loss 
of ATRX led to defects in chromosome alignment along the meiotic spindle during 
metaphase II (De La Fuente et al., 2004). These authors proposed a role for ATRX in 
binding to centromeric heterochromatin, to mediate proper chromosome alignment during 
meiosis.  
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1.4.8 DNA replication & repair 
 
The previous studies cited support a clear link between ATRX loss and replicative stress 
in proliferating cells, suggesting ATRX is required to maintain genomic stability during 
replication. More recently, studies have defined a role for ATRX in preventing 
replication fork stalling, which lead to collapse and double-stranded DNA breaks (DSBs) 
if unresolved by DNA repair responses (Branzei and Foiani, 2010; Clynes et al., 2014; 
Huh et al., 2016). It has been proposed that ATRX prevents the formation of DNA 
secondary structures during replication that lead to these stalled replication forks 
(Gibbons et al., 2010). ATRX binds to tandem-repeat sequences (Law et al., 2010), 
which are often guanine-rich (G-rich) sequences and have the propensity to form 
secondary DNA structures called G-quadruplexes (G4; Duquette et al., 2004). G-
quadruplexes are abnormal and form potential obstacles for normal DNA processes 
including DNA replication and transcription (Rizzo et al., 2009; Levy et al., 2014) and 
stabilization of these G4 structures induces replicative stress (Rizzo et al., 2009; 
Rodriguez et al., 2012). Approximately 50% of ATRX binding sites indicated by ChIP 
were predicted to form G4 structures, and electrophoretic mobility shift assays indicated 
ATRX interacted with G4 DNA in vitro (Law et al., 2010). ATRX is believed to 
incorporate H3.3 into G-rich sequences to prevent G4 DNA formation and allow the 
proper passage of transcriptional machinery (Gibbons et al., 2010; Levy et al., 2014). In 
support of this mechanism, Atrx-null neuroprogenitor cells had increased susceptibility to 
treatment with a G4-stabilizing ligand (Watson et al., 2013).  
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In addition to the prevention of replication fork stalling, ATRX may also play a role in 
recruiting DNA repair complexes to resolve stalled forks. ATRX and the MRE11-
RAD50-NBS1 (MRN) complex interact to facilitate replication fork restart and repair 
double stranded breaks (Clynes et al., 2014; Leung et al., 2013), indicating a role for 
ATRX in DNA repair. Loss of ATRX increases DNA damage in mouse ES cells (Clynes 
et al., 2014), and enhance sensitivity to a variety of DNA damaging agents (Conte et al., 
2012). An apparent link exists between loss of ATRX and activation of p53, with the 
occurrence of p53-mediated apoptosis in Atrx-null neuroprogenitors and myoblasts 
(Conte et al., 2012; Watson et al., 2013; Huh et al., 2012).   
 
1.4.9 Telomere maintenance & Alternative Lengthening of Telomeres 
(ALT) 
 
In mouse embryonic stem cells, ATRX localized to telomeres with H3.3 during 
replication in the S-phase, and RNAi knockdown of Atrx led to telomere dysfunction 
(Wong et al., 2010). Deletion of Atrx in mouse neuroprogenitor cells lead to increased 
telomere fusion, and other telomeric defects including deletions and duplications (Watson 
et al., 2013). These studies indicate a role for ATRX-mediated telomere maintenance, 
which is supported by the upregulation of the alternative lengthening of telomeres (ALT) 
pathway that occurs with ATRX loss (Lovejoy et al., 2012; Clynes et al., 2015; Bower et 
al., 2012).  
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ALT is a mechanism through which telomeres maintain their length independent of 
telomerase enzyme by using homologous recombination (HR) (Bryan et al., 1997; 
Dunham et al., 2000). ALT is believed to be utilized in 10-15% of cancers but varies 
based on cancer type (Heaphy et al., 2011b). A role for ATRX in suppression of the ALT 
pathway has been well-established, although loss of ATRX alone is not sufficient to drive 
ALT (Clynes et al., 2014). A study of 22 ALT-positive cell lines demonstrated 90% were 
negative for ATRX (Lovejoy et al., 2012), while use of somatic cell hybrids 
demonstrated a correlation between ATRX loss and presence of the ALT pathway 
(Bower et al., 2012). Ectopic ATRX expression reversed the ALT phenotype, and 
ATRX-mediated suppression of the ALT pathway was dependent on DAXX (Clynes et 
al., 2015). These findings suggest a mechanism in which ATRX stabilized telomeric 
regions using H3.3 incorporation, preventing the formation of secondary DNA structures 
leading to double-stranded DNA breaks and subsequent HR. 
 
1.4.10 Malignancies involving ATRX mutation 
 
Given the previously described roles of ATRX in cell cycle processes, DNA replication 
and repair and telomere maintenance, it is not unexpected that ATRX mutations have been 
implicated in several types of cancer. One of the first reported cases of acquired, somatic 
ATRX mutations occurred in patients with a-thalassemia myelodysplasia syndrome 
(ATMDS; Gibbons et al., 2003). Additional studies identified ATRX mutations in several 
types of diffuse gliomas, including astrocytomas and glioblastomas (Jiao et al., 2012; 
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Kannan et al. 2012; Wiestler et al., 2013). Mutation frequency in adult gliomas is 
distributed evenly across the ATRX gene, and typically result in frameshifts or nonsense 
mutations (Jiao et al., 2012). These mutations often co-occur with TP53 or IDH1 
mutations, and are correlated to the presence of ALT (Jiao et al., 2012; Kannan et al., 
2012; Schwartzentruber et al., 2012). Assessment of ATRX in glioma can be prognostic 
(Pekmezci et al., 2017; Karsy et al., 2017), and ATRX loss has been indicated as a 
favourable prognostic factor in a subset of astrocytic tumours (Wiestler et al., 2013). In 
cases of paediatric glioblastoma, in which ATRX is mutated in approximately 30% of 
patients, mutations are typically found near the carboxy-terminal helicase domain 
(Schwartzentruber et al., 2012). ATRX mutations have also been implicated in paediatric 
osteosarcomas (Ellison et al., 2014; Lovejoy et al., 2012), and melanomas (Qadeer et al., 
2014). ATRX has been suggested to act as a negative regulator of histone variant macro 
H2A1.2, which is linked to melanoma progression (Ratnakumar et al., 2012). In contrast 
to many other cancer types, ATRX is over-expressed in colorectal cancer cell lines 
(Athwal et al., 2015), and may cooperate with DAXX to incorporate the histone variant 
CENP-A into chromatin, altering the normal chromatin state. 
 
1.4.11 ATRX mutation in pancreatic neuroendocrine tumours 
(PNETs) 
 
ATRX mutations have been implicated in pancreatic neuroendocrine tumours (PNETs), a 
rare type of tumour with demonstrated chromosomal instability (Hu et al., 2010). 
Genomic analysis on 68 cases of PanNETs identified mutations for ATRX or DAXX in 
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43% of samples, while 44% contained mutations in the MEN1 tumour suppressor gene 
(Jiao et al., 2011). In the majority of ATRX-mutated cases, deletions or insertions and 
nonsense mutations in the ATRX gene lead to loss of the ATRX protein (Jiao et al., 2011). 
Mutations in ATRX and DAXX are almost always mutually exclusive, indicating they 
perform similar functions in a tumour-suppressive role (Jiao et al., 2011; Yachida et al., 
2012). Loss of DAXX or ATRX was strongly correlated to the ALT phenotype, and the 
presence of chromosomal instability in PNETs (Heaphy et al., 2011a; Marinoni et al., 
2014). Conflicting reports exist on the prognosis of DAXX/ATRX mutations in PNETs, 
and their effect on long-term survival is unclear. However, a recent study by Singhi et al 
(2017) demonstrated that DAXX/ATRX loss in PanNETs resulted in higher rates of 
metastasis and a poor survival rate. Within the exocrine pancreas, there is currently 
limited information regarding ATRX loss and PDAC.  
 
1.5 Rationale, Hypothesis & Objectives 
 
Pancreatic ductal adenocarcinoma (PDAC) is a rare but lethal disease of the exocrine 
pancreas, with a five-year survival rate of less than 6%. Constitutively activating KRAS 
mutation (KRASG12D) is present in greater than 95% of PDAC cases, but KRAS mutation 
alone is insufficient to drive PDAC progression. Additional factors, such as acquired 
somatic mutation or pancreatic injury, are required to promote disease progression. 
Previous studies have implicated a role for chromatin remodelers, including BMI1 (von 
Figura et al., 2014a), in constraining KRASG12D-mediated PDAC. However, the role of 
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chromatin remodeling protein ATRX has not yet been characterized in the context of the 
exocrine pancreas. In other tissues, ATRX is shown to play a role in many cellular 
processes including gene regulation, cell cycle progression, DNA replication and 
telomere maintenance. In the exocrine pancreas, ATRX loss could alter these processes, 
influencing acinar cell function or response to pancreatic insult, including pancreatitis or 
oncogenic KRAS activation.  
 
It is hypothesized that inducible deletion of Atrx will increase the susceptibility of 
acinar cells to pancreatic injury or KRASG12D oncogenic transformation. Two main 
objectives were completed to address this hypothesis. First, mice with acinar cell-specific 
inducible Atrx deletion underwent recurrent pancreatic injury to determine the role of 
ATRX in the acinar cell response to injury. Second, acinar cell-specific Atrx deletion was 
combined with oncogenic KRASG12D activation in mice to determine the role of ATRX in 
constraining KRAS-mediated oncogenic transformation. This work defines a novel role 
for ATRX in disease progression in the exocrine pancreas, and provides further insight 
into acinar cell factors that influence susceptibility to pancreatic disease.  
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Chapter 2  
2 Methods 
 
2.1 Animal Care and Cre Induction 
 
All mouse experiments were approved by the Animal Care and Use Committee at the 
University of Western Ontario (Protocol #2017-001). Male and female C57Bl6 mice 
expressing creERT from the Mist1 locus (Mist1creERT/+; Shi et al., 2013) were crossed 
with mice harboring an Atrx allele with the 18th exon flanked by loxP sites (Berube et al., 
2005), producing male (Mist1creERT/+AtrxflΔ18/y) and female (Mist1creERT/+AtrxflΔ18/fl Δ18) 
mice, collectively referred to as Mist1creERT/+AtrxflΔ18. Control mice were considered mice 
heterozygous for the creERT allele (Mist1creERT/+) or wildtype for Mist1 (Mist1+/+), and 
were collectively referred to as Mist1creERT/+, as previous literature and extensive work in 
our laboratory has established no difference in phenotype between mice wild-type or 
heterozygous for Mist1 expression (Karki et al., 2015; unpublished data).  
 
Mist1creERT/+AtrxflΔ18 mice were also crossed to mice containing an inducible form of 
oncogenic KRAS (loxP-STOP-loxP (LSL)-KRASG12D), to produce Mist1creERT/+LSL-
KRASG12DAtrxflΔ18 mice (referred to as MKA). In 2-4 month old mice, tamoxifen (Sigma-
Aldrich, St. Louis, MO, USA) was administered through oral gavage (2 mg/mouse), three 
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times over five days. Mice were monitored for a period of 60 days from first tamoxifen 
gavage, and body weight was measured weekly. 
 
2.2 Cerulein Induced Pancreatitis (CIP) 
 
To induce recurrent pancreatic injury, 60 days following tamoxifen gavage, control 
(Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice (see Table 2.1 for n values) were given 
intraperitoneal injections of cerulein (Sigma-Aldrich, St. Louis, MO, USA, 75 µg/kg 
body weight), twice daily for 11 days, followed by a three-day recovery period. Saline 
injections were used as a control. Mice were weighed daily throughout the pancreatitis 
protocol. Three days following cessation of cerulein treatment, mice were sacrificed and 
pancreatic tissue was collected for analysis. 
 
2.3 Serum Amylase Assay 
 
Immediately following euthanasia, blood was collected from mice through intra-cardiac 
puncture and placed on ice for 30 minutes. Blood samples were centrifuged at 3,000 rpm 
at 4°C for 15 minutes, and supernatant (blood serum) collected. Levels of serum amylase 
were determined using the Phadebas amylase test (Magle Life Sciences, Cambridge, 
MA, USA), according to kit instructions. Briefly, serum samples were diluted in buffer 
(0.9% NaCl, 0.2% bovine-serum albumin [BSA], 20 mM CaCl2), placed in 4 mL distilled 
 41 
water and incubated at 37ºC for 5 min. A Phadebas tablet was placed in each tube, 
incubated at 37ºC for 15 min, and then 1 mL of 0.5M NaOH was added to each sample. 
Samples were centrifuged at 1500 rpm for 5 min, and absorbance of the supernatant was 
measured at 620 nm, using the Ultrospec 2100 pro UV/Visible spectrophotometer 
(Thermo Fisher Scientific, Fremont, CA, USA). 
 
2.4 Histological Quantification and Analysis 
 
Mouse pancreata (taken from the head-mid region of the pancreas) were fixed overnight 
in 4% formalin, washed with phosphate-buffered saline (PBS) for 24 hours, and placed in 
70% ethanol prior to embedding in paraffin. Paraffin tissue sections (5 µm thickness) 
were stained using standard H&E, Alcian Blue or Masson’s Trichrome stain (ab150686; 
Abcam Inc.) protocols. The Alcian Blue kit used was specific to pH 2.5 to target all 
acidic mucins (Mucin Stain; ab150662; Abcam Inc.). Sections were imaged using the 
Aperio CS2 Digital Scanner and Aperio ImageScope software (Leica Biosystems 
Imaging Inc, San Diego, CA, USA). Levels of pancreatic damage in recurrent pancreatic 
injury and KRASG12D models were assessed using a grading scale based on three factors - 
fibrosis, inflammation and presence of acinar to ductal metaplasia. Tissue sections were 
scored on a scale from 0 – 4. Representative images and descriptions of each score can be 
found in Supplementary Figure S1; Supplemental Table S1. 
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Total tissue area was quantified using the Fiji software (Schindelin et al., 2012), and area 
of damage was quantified as a percentage of total area. Total number of pancreatic 
lesions (between 0-800, ranging from ADM to PanIN grade 3) were quantified and 
classified into the following categories; ADM, PanIN grade 1, PanIN grade 2, PanIN 
grade 3, based on morphological characteristics including cell shape (cuboidal or 
columnar), presence of mucin accumulation, nuclear atypia, pseudostratification and 
papillary or cribriform structure (see Supplemental Figure S5 for examples).  
 
2.5 Immunohistochemistry (IHC) and Immunofluorescence 
(IF) 
 
For immunohistochemical analysis (IHC), paraffin tissue sections (5 µm thickness) were 
stained using the ABC staining system (Santa Cruz Biotechnology Inc., Dallas, TX, sc-
2018/2017) or the VectaStain ABC HRP kit with ImmPACT DAB Peroxidase (HRP) 
Substrate (Vector Laboratories, PK-4001/SK-4105, Brockville, ON, CA) according to kit 
instructions, counterstained with hematoxylin and coverslipped using Permount 
Mounting Medium (Thermo Fisher Scientific). Cleaved-caspase 3 staining was 
completed using the Ventana Discovery Ultra XT autostainer (Ventana Medical Systems 
Inc, Tuscon, AZ). Slides were imaged at 20x and 40x magnification using light 
microscopy (Leica DFC450 microscope camera on the Leica DM5500B microscope; 
Leica Microsystems Ltd., Wetzlar, Germany) with Leica LAS V4.4 software. Primary 
antibodies used are specific to ATRX (diluted in 1.5% mouse blocking serum in PBS, 
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1:100; Santa Cruz Biotechnology Inc.), carboxypeptidase (CPA; 1:1000; Abcam), SOX9 
(1:500; Abcam Inc., Cambridge MA), PDX1 (1:1000; Abcam Inc.), Ki67 (1:500; Abcam 
Inc.) and cleaved caspase 3 (1:100; Cell Signaling Technology, Danvers, MA). 
 
For immunofluorescence (IF), mouse pancreata were frozen in cryomatrix and sectioned 
into 6 µm sections. Tissue sections were kept at -20°C until processing, then warmed to 
room temperature and fixed in 4% formalin for 10 min, followed by 0.1% Triton in PBS 
for 10 min. Slides were placed in blocking solution (0.1% Triton X-100 in 5% BSA in 
PBS) for 30 min, and incubated in primary antibody overnight at 4°C. Following three 5 
min PBS washes, slides were incubated in secondary antibody for 1 h at room 
temperature (RT), washed with PBS, stained with 4',6-diamidino-2-phenylindole (DAPI) 
and mounted with Permafluor mountant (Thermo Fisher Scientific). Slides were imaged 
at 40x magnification using fluorescence microscopy (Leica DFC365 FX camera on the 
Leica DM5500B microscope; Leica Microsystems Ltd.), and Leica LAS V4.4 software. 
Primary antibodies used are specific to ATRX (diluted in blocking solution, 1:100; Santa 
Cruz Biotechnology Inc.), MIST1 (1:500; Pin et al., 2000), b-catenin (1:500; Sigma), 
Insulin (1:500; Sigma), or gH2AX (1:200; Santa Cruz Biotechnology Inc.). Secondary 
antibodies used include anti-rabbit FITC and anti-mouse FITC (1:250; Jackson 
ImmunoResearch, West Grove, PA).  
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2.6 Protein Isolation & Western Blot Analyses 
 
Mouse pancreata were flash frozen in liquid nitrogen immediately following dissection, 
then homogenized in a protein isolation buffer consisting of: 50 mM Tris pH 7.2, 5 mM 
MgCl2, 1 mM CaCl2, 10 mM DTT, 1% Nonidet P-40, DNAse (100 units/ml), RNAse (50 
µg/ml), 1 mM PMSF, 30 mM NaF, 2 mM Na3VO4 and protease inhibitors leupeptin, 
aprotinin and pepstatin (5 µg/ml each). Once homogenized, samples were sonicated for 
20 seconds, centrifuged at 14,000 rcf for 5 min at 4°C, and supernatant was retained. 
Protein concentrations were quantified using the Bradford protein assay (Bio-Rad, 
Hercules, CA). Isolated protein was resolved by SDS-PAGE in 10% acrylamide gels and 
transferred to a PVDF membrane (Bio-Rad) at 200 mA for 90 minutes. Blots were 
blocked with 5% non-fat dried milk (NFDM) and incubated in primary antibody 
overnight at 4°C in 5% NFDM (total ERK1/2 and SOX9 antibodies were incubated in 
5% BSA-0.1% Tween20). Following incubation, blots were washed in PBS-0.1% 
Tween20, 4x for 5 min, then incubated in secondary antibody (anti-rabbit HRP, 1:10,000; 
Jackson Labs, Bar Harbor, ME) in 5% NFDM for 1 h at room temperature. Blots were 
washed 4x for 5 min in PBS-0.1% Tween20, and developed using Western Lightening 
chemiluminescence substrate (Perkin Elmer, Waltham, MA). Blots were visualized using 
the VersaDoc system with Quantity One 1-D analysis software (Bio-Rad). Primary 
antibodies used were specific for SOX9 (1:500; Abcam), CPA (1:1000; Abcam), amylase 
(1:1000; Abcam) and p44/42 MAPK (ERK1/2) (1:2500, Cell Signaling Technology).  
 45 
2.7 TUNEL Assay 
 
To assess apoptosis, 6 µm pancreatic sections were fixed in 4% formalin for 10 min at 
room temperature, washed with PBS for 3x for 5 min and permeabilized with 0.1% 
Triton X-100 in 0.1% sodium citrate in PBS, for 2 min on ice. Using the In Situ Cell 
Death detection kit (Roche, Laval, QC, CA), slides were labelled with the TUNEL 
reaction mixture for 1 h at 37°C. Following three PBS washes, slides were stained with 
DAPI and mounted with Permafluor mountant (Thermo Fisher Scientific).  The number 
TUNEL-positive cells was quantified using 7 random fields of view from each mouse, 
and calculated as percentage of TUNEL positive cells compared to DAPI counts.  
 
2.8 Quantitative real-time PCR 
 
RNA was isolated from splenic pancreatic tissue using TRIZOL (Invitrogen, Carlsbard, 
CA, USA), and the SV Total RNA Isolation system (Promega, Madison, WI). Briefly, a 
small piece of pancreatic tissue (>2 cm wide) was immediately placed in 5 mL TRIZOL 
and homogenized for 30 sec. The solution was mixed after the addition of 1 mL 
chloroform, incubated at 4°C for 3 min and centrifuged (4°C) for 15 min. The 
supernatant was removed and washed 4x with 70% ethanol. DNase was added to the 
RNA for 15 min at RT, followed by DNase stop solution, 2 washes, and elution of RNA 
in RNase-free water. 1 µg of RNA was reverse-transcribed using ImPromII Reverse 
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transcriptase (Sigma). Quantitative RT-PCR (qRT-PCR) was carried out using primers 
specific to the Mist1 gene: 
 Fwd: 5' GTGGTGGCTAAAGCTACGTG 3' 
Rev: 5' GACTGGGGTCTGTCAGGTGT 3' 
and the GoTaq PCR Mastermix system (Promega, Madison, WI, USA) using an ABI 
Prism 7900HT Sequence Detection System and SDS 2.2.1 software (Applied Biosystems, 
Foster City, CA, USA).   
  
2.9 Statistical Analysis 
 
Data was analyzed for significance using an unpaired, two-tailed T-test or two-way 
ANOVA with Tukey’s post-hoc test with GraphPad Prism 6 software. Values are 
depicted as means ± standard error of the mean (SEM). Significance is considered 
p<0.05.  
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Chapter 3  
3 Results 
 
To determine if ATRX affected the phenotype of mature acinar cells, mice with exon 18 
in the Atrx gene flanked by loxP sites (Berube et al., 2005) were mated to mice 
expressing an inducible cre recombinase from the Mist1 locus (Shi et al., 2013). Since 
ATRX is an X-linked gene, male mice are referred to as Mist1creERT/+ AtrxflΔ18/y and 
female mice are Mist1creERT/+ AtrxflΔ18/ flΔ18. These mice will collectively be referred to as 
Mist1creERT/+ AtrxflΔ18 hereafter (Figure 3.1). The Mist1 gene (driving creERT) is 
expressed in serous exocrine cells of the pancreas but not duct or centroacinar cells of the 
pancreas (Pin et al., 2000). Tamoxifen induced cre recombination was induced in 2-4 
month-old mice and ATRX accumulation assessed 7, 35 or 60 days after dosing (Figure 
3.2A, B). Immunofluorescent (IF) analysis indicated 98% of the acinar cells were ATRX-
negative 7 days following tamoxifen gavage, demonstrating efficient Atrx deletion. Two 
months post-gavage, 98% of cells remained negative for ATRX, indicating mature acinar 
cells can survive without ATRX expression (Figure 3.2B). IF co-staining for ATRX with 
insulin, a marker of pancreatic islets, demonstrated ATRX expression in islets, while 
surrounding acinar tissue was largely devoid of ATRX expression (Figure 3.2C). ATRX 
expression remained visible in other non-acinar cell types, including ductal, centroacinar 
and interstitial cells (Figure 3.2A, C; white arrows) based on nuclear morphology and 
tissue location. 
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Since ATRX can affect mitosis and DNA repair (Ritchie et al., 2008; Clynes et al., 2014; 
Conte et al., 2012; Leung et al., 2013), the levels of DNA damage and acinar cell death 
were examined 60 days following tamoxifen treatment. Assessment of gH2AX 
accumulation showed an increased presence in DNA double stranded breaks in 
Mist1creERT/+AtrxflΔ18 mice, suggesting increased DNA damage with loss of ATRX 
(Supplemental Figure S2; Figure 3.2D). Furthermore, TUNEL analysis demonstrated 
increased acinar cell apoptosis (Supplemental Figure S2; Figure 3.2E), suggesting 
ATRX loss caused mild injury or cell stress in a subset of acini. Assessment of MIST1 
expression levels, a marker of the mature acinar cell which is down-regulated during 
injury (Fazio et al., submitted) indicated decreased MIST1 accumulation by IF, and a 
trend towards a reduction in Mist1 mRNA in Mist1creERT/+ AtrxflΔ18 pancreatic tissue 
(Figure 3.2F). Combined these results suggest the loss of Atrx results in a mild 
pancreatic injury, which may make the pancreas susceptible to additional stress. 
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Figure 3.1. Schematic of Atrx deficient mouse model. Cre-recombination events driven 
by expression from the Mist1 promoter produces deletion of exon 18 of the Atrx gene, in 
combination with expression of oncogenic KRASG12D in 2-4 month old mice. 
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Figure 3.2. Mature acinar cells do not require ATRX for survival, but ATRX loss 
induces low levels of pancreatic damage. (A) Immunofluorescence (IF) for ATRX 
expression in pancreatic tissue 7 (n=8), 35 (n=3), and 60 (n=4) days following tamoxifen 
gavage. White arrows indicate ATRX expression in non-acinar cell types, based on nuclei 
morphology. (B) Efficiency of Atrx deletion was quantified as percentage of acinar cells 
lacking ATRX expression. (C) IF for ATRX and insulin, a marker of pancreatic islets, 
demonstrates acinar-specific knockout of ATRX expression in Mist1creERT/+AtrxflΔ18 mice. 
White arrows indicate ATRX expression in non-acinar cell types. (D) Quantification of 
gH2AX-positive acinar cells in control (Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice 
shows increased presence of double-stranded DNA breaks in cells lacking ATRX 
(Mist1creERT/+, n=7; Mist1creERT/+AtrxflΔ18, n=11; * denotes p=0.004). (E) Quantification of 
TUNEL-positive apoptotic cells in control (Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice 
demonstrate increased acinar cell death with loss of ATRX (Mist1creERT/+, n=9; 
Mist1creERT/+AtrxflΔ18, n=10; * denotes p=0.0006). (F) IF staining for MIST1 protein 
expression indicates decreased MIST1 in Mist1creERT/+AtrxflΔ18 mice, as supported by 
qRT-PCR (Mist1creERT/+, n=4; Mist1creERT/+AtrxflΔ18, n=6; p=0.058 indicated by t-test). In 
all cases, bars represent means ± standard error. 
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3.1 Loss of ATRX increases susceptibility to recurrent 
pancreatic injury 
 
To determine if the mild injury observed in Mist1creERT/+AtrxflΔ18 mice affects the 
pancreatic response to recurrent injury, Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice were 
subjected to recurrent pancreatic injury for 11 days (Figure 3.3A) and then allowed to 
recover for three days. Upon dissection, no gross morphological differences were 
observed between Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice (data not shown), and no 
significant difference in body weight was observed between groups, either prior to or 
throughout pancreatic injury (Figure 3.3B). Assessment of serum amylase levels, a 
marker of pancreatitis severity, revealed no differences between groups (Figure 3.3C). 
However, histological analysis showed marked differences between these two groups. 
Cerulein-treated Mist1creERT/+ mice show limited differences when compared to saline-
treated controls, with the presence of intra-acinar edema (Figure 3.4A). This was 
unexpected but suggests that the cerulein dosing regime was suboptimal to produce levels 
of damage typically observed in recurrent pancreatic injury protocols, and resulted in 
minimal damage to the tissue. Conversely, cerulein-treated Mist1creERT/+AtrxflΔ18 mice 
show increased inflammation, potential acinar-to-ductal metaplasia (ADM; Figure 3.4A; 
Table 3.1), and increased levels of fibrosis, as indicated by Trichrome stain analysis 
(Figure 3.4B; Table 3.1). Surprisingly, this damage appears to be more extensive in 
Mist1creERT/+AtrxflΔ18 female mice (Table 3.1).  
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Figure 3.3. No alteration in body weight and serum amylase levels between cerulein-
treated Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice. (A) Experimental timeline for 
recurrent pancreatic injury model in 2- 4 month old congenic Mist1creERT/+ or 
Mist1creERT/+AtrxflΔ18 mice. (B) Percent change in body weight of mice during prior to and 
during recurrent CIP (red arrow indicates cessation of treatment). (C) Serum amylase 
levels in mice (n=4-5 for each group) three days following cessation of recurrent CIP 
treatment. Bars represent mean ± standard error. No significant difference in body weight 
or amylase levels was observed between genotypes.    
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Figure 3.4. Loss of ATRX increases susceptibility to recurrent pancreatic injury. (A) 
Representative H&E staining of saline or cerulein (CIP) treated Mist1creERT/+ and 
Mist1creERT/+AtrxflΔ18 mice three days following cessation of pancreatic injury. 
Mist1creERT/+ CIP-treated mice show intra-acinar edema relative to saline-treated control 
mice. CIP-treated Mist1creERT/+AtrxflΔ18 mice demonstrate increased pancreatic damage, 
fibrosis and putative ADM relative to CIP-treated Mist1creERT/+ mice (black arrows 
indicate the presence of inflammatory cells in CIP-treated Mist1creERT/+AtrxflΔ18 mice). 
Similar analysis suggests that Mist1creERT/+AtrxflΔ18 female mice show more extensive 
injury. Representative scale bar is indicated for each panel. (B) Representative Trichrome 
stain of Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 pancreatic tissue, three days following 
cessation of CIP treatment, indicating the level of fibrosis present throughout the tissue. 
Mist1creERT/+AtrxflΔ18 mice exhibit increased fibrosis based on Trichrome staining 
(presence of blue indicates fibrotic areas, indicated by black arrow), to a greater extent in 
female Mist1creERT/+AtrxflΔ18 mice. 
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Table 3.1. Morphometric analysis of pancreatic tissue following recurrent 
pancreatic damage 
 
 
 
 
 
 
 Male Female 
 Mist1creERT/+ (5) Mist1
creERT/+AtrxflΔ18
(5) Mist1
creERT/+ (4) Mist1
creERT/+AtrxflΔ18 
(5) 
Fibrosis 0 0 0 1.4 
Inflammation 0.2 1.4 0.75 2.4 
ADM 0 0.6 0 1.2 
Total 0.2±0.2 2.0±0.45 0.75±0.25 5.0±1.1 
(#) – indicates n value; see methodology for scoring. Histopathological assessment of pancreatic damage, as 
indicated by three factors; fibrosis, inflammation and the presence of ADM. Scores are represented on a grading 
scale from 0 – 4. There are increased levels of pancreatic damage in cerulein-treated Mist1creERT/+AtrxflΔ18 
 mice compared to other groups. 
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To determine if increased damage observed in Mist1creERT/+AtrxflΔ18 mice following injury 
correlates with increased levels of apoptosis, cleaved caspase-3 levels in acinar tissue 
were quantified using IHC (Figure 3.5). Results demonstrated no significant differences 
in levels of apoptosis between genotypes or genders. Similarly, assessment of 
proliferation in cerulein-treated Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice revealed no 
significant differences (Figure 3.6), indicating a change in apoptosis or proliferation was 
likely not a primary factor through which loss of ATRX altered the response to pancreatic 
injury (Figure 3.6).  
 
ADM are identified by a reduction in differentiated acinar cell markers (including 
amylase, carboxypeptidase (CPA)), and a concomitant increase in progenitor/ductal 
markers (including SOX9) that are not typically expressed in acinar tissue (Karki et al., 
2015; Pinho et al., 2011; Prevot et al., 2012). In wild-type pancreatic tissue, the 
transcription factor SOX9 is expressed only in ductal and centroacinar cells (Prevot et al., 
2012). Previous studies showed SOX9 upregulation in both ADM and advanced 
pancreatic lesions (Kopp et al., 2012; Prevot et al., 2012). Three days following cessation 
of pancreatic injury, histological analysis suggested increased instances of ADM in 
Mist1creERT/+AtrxflΔ18 mice relative to Mist1creERT/+ mice. To confirm the increased ADM 
within Mist1creERT/+AtrxflΔ18 mice following injury, acinar tissue was examined for the 
presence of amylase, carboxypeptidase or SOX9. In corroboration with the histological 
analysis, IHC showed a consistent and significant decrease in CPA staining in female 
Mist1creERT/+AtrxflΔ18 mice, in response to chronic injury (Figure 3.7A), which was not 
observed in Mist1creERT/+ mice or Mist1creERT/+AtrxflΔ18 male mice. Western blot analyses 
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confirmed decreased CPA in Mist1creERT/+AtrxflΔ18 cerulein-treated mice of both genders, 
compared to cerulein-treated control mice (Figure 3.7B). Conversely, Mist1creERT/+ 
cerulein-treated mice exhibited an upregulation of CPA compared to saline-treated 
controls. Amylase levels are also upregulated in cerulein-treated Mist1creERT/+ mice but 
not in cerulein-treated Mist1creERT/+AtrxflΔ18 mice (Figure 3.7B).  
 
IHC analysis for SOX9 showed increased nuclear staining in Mist1creERT/+AtrxflΔ18 
pancreatic tissue following CIP treatment (Figure 3.7A), although no increase in total 
Sox9 levels was observed by Western blot analyses (Figure 3.7B). Taken together, this 
data suggests loss of ATRX increases the sensitivity of acinar cells to recurrent 
pancreatic injury, leading to upregulation of progenitor markers, consistent with 
increased tissue damage and ADM.  
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Figure 3.5. Acinar-specific apoptosis is not significantly altered between Mist1creERT/+ 
and Mist1creERT/+AtrxflΔ18 mice during recurrent CIP. (A) IHC analysis reveals 
variation in cleaved caspase 3 staining in Mist1creERT/+ (n=4 for both saline and cerulein-
treated groups) and Mist1creERT/+AtrxflΔ18 mice (male Mist1creERT/+AtrxflΔ18 saline n=4, 
remaining groups n=5) of both genders (black arrows indicate acinar cells positive for 
caspase-3). Images demonstrate areas of high staining in cerulein-treated 
Mist1creERT/+AtrxflΔ18 mice, although there is variability present within the tissue. (B) 
Quantification of percentage of acinar cells positive for cleaved caspase 3 expression. 
Bars represent mean ± standard error.  
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Figure 3.6. Acinar cell proliferation is not significantly altered between Mist1creERT/+ 
and Mist1creERT/+AtrxflΔ18 mice following CIP. (A) Representative IHC for Ki67 
accumulation, indicating variation in the number of acinar cells undergoing proliferation 
in Mist1creERT/+ (n=3) and Mist1creERT/+AtrxflΔ18 mice (n=3), following recurrent pancreatic 
injury. Black arrows indicate Ki67-positive acinar cells. Images demonstrate areas of 
high Ki67 staining present within tissue, although there is variability throughout the 
tissue. (B) Quantification of percentage of acinar cells positive for Ki67 expression. Bars 
represent mean ± standard error.  
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Figure 3.7. Mist1creERT/+AtrxflΔ18 pancreatic tissue shows decreased digestive enzyme 
accumulation, and increased SOX9 staining. (A) IHC analysis for carboxypeptidase 
(CPA) and SOX9 in Mist1creERT/+ or Mist1creERT/+AtrxflΔ18 mice, three days following 
cessation of recurrent CIP treatment. CPA staining was decreased in female 
Mist1creERT/+AtrxflΔ18 mice (acinus is indicated by a dotted line). Conversely, SOX9 
staining was increased in both male Mist1creERT/+AtrxflΔ18 and female Mist1creERT/+AtrxflΔ18 
tissue (black arrows). Higher magnification images show specific SOX9 staining. (B) 
Representative Western blot analysis for CPA and amylase indicated increased digestive 
enzymes specifically in Mist1creERT/+ mice, while Mist1creERT/+AtrxflΔ18 mice demonstrated 
decreased enzymes. Total ERK1/2 (tERK1/2) was used as a loading control. 
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3.2 The loss of ATRX enhances oncogenic KRAS-induced 
pancreatic injury in female mice 
 
If loss of Atrx increases the potential for ADM, this would suggest that 
Mist1creERT/+AtrxflΔ18 mice would be more susceptible to oncogenic KRAS activation, as 
maintenance of the acinar phenotype is shown to be important in constraining KRAS-
induced transformation (Shi et al., 2013; von Figura et al., 2014b; Martinelli et al., 2015). 
Further, chronic forms of pancreatic injury, which demonstrate sustained ADM, are a 
significant risk factor for the development of PDAC (Malka et al., 2002; Lowenfels et al., 
1993).  To assess the potential for increased damage with oncogenic KRAS, 
Mist1creERT/+AtrxflΔ18 mice were mated to mice containing an inducible form of oncogenic 
KRAS (LSL-KRASG12D) to generate Mist1creERT/+LSL-KRASG12DAtrxflΔ18 mice (hereafter 
referred to as MKA mice) (Figure 3.8A). Control female mice included mice that are 
heterozygous (Mist1creERT/+AtrxflΔ18/x) or wild-type (Mist1creERT/+Atrxx/x) for the Atrx allele, 
and will collectively be referred to as Mist1creERT/+ mice. Similarly, female mice with 
KRAS activation that were heterozygous for Atrx expression (Mist1creERT/+LSL-
KRASG12DAtrxflΔ18/x), or wild-type for Atrx expression (Mist1creERT/+LSL-KRASG12DAtrxx/x) 
are collectively referred to as female Mist1creERT/+LSL-KRASG12D mice.  
 
Cre-recombinase-mediated induction of KRASG12D and/or deletion of Atrx was performed 
in 2- 4 month old congenic Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-
KRASG12D and MKA mice, which were followed for two months prior to sacrifice (Figure 
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3.8A). Again, efficient Atrx deletion was confirmed using IHC (Figure 3.8B). There was 
no significant difference observed in body weight between groups (Figure 3.8C), and 
assessment of serum amylase levels revealed no differences (Figure 3.8D). Initial gross 
examination of the pancreas in situ demonstrated variability in the appearance of 
pancreatic tissue between groups, with the presence of enlarged spleens in both female 
Mist1creERT/+LSL-KRASG12D and MKA mice, and evidence of edema in female MKA mice 
(Supplemental Figure S3).  
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Figure 3.8. Combined Atrx deletion with oncogenic KRAS activation does not alter 
body weight of mice. (A) Experimental timeline for tamoxifen gavage in 2-4 month old 
congenic Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D (denoted as LSL-
KRASG12D) and MKA mice. (B) IHC revealed ATRX expression in acinar (black arrow) 
and duct (red arrow) cells of Mist1creERT/+ mice. In Mist1creERT/+AtrxflΔ18 mice, ATRX 
expression was limited to islets (open arrow) and duct cells (red arrow). (C) Change in 
body weight (%) of mice (both genders) following Atrx deletion +/- oncogenic KRAS 
activation showed no significant differences (Mist1creERT/+AtrxflΔ18 denoted as AtrxflΔ18, 
Mist1creERT/+LSL-KRASG12D denoted as LSL-KRASG12D). Points are represented as mean 
weight ± standard error. (D) Serum amylase levels in mice (n=3-8 in each group), two 
months following Atrx deletion +/- oncogenic KRAS activation. Bars represent mean ± 
standard error. 
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Previous reports suggest that on its own, activation of oncogenic KRASG12D in mature 
acinar cells is insufficient to cause widespread pancreatic damage (Morris et al., 2010b; Ji 
et al., 2009). Accordingly, Mist1creERT/+LSL-KRASG12D mice demonstrated normal 
pancreatic morphology, with few instances of ADM or more progressive PanIN lesions 
(Figure 3.9). However, MKA mice demonstrated increased in levels of pancreatic 
damage, but exclusively in females (Figure 3.9). Female MKA mice also exhibited 
increased levels of inflammation and fibrosis, along with disruption to the normal acinar 
cell organization (Figure 3.9; Table 3.2), relative to all other groups. Interestingly, male 
MKA mice exhibited little to no pancreatic damage, even to a lesser extent than male 
Mist1creERT/+LSL-KRASG12D mice.  
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Figure 3.9. Female Mist1creERT/+AtrxflΔ18 mice show increased sensitivity to oncogenic 
KRAS activation. Representative H&E images of pancreatic tissue from male and 
female Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D and MKA mice 60 
days after tamoxifen treatment. Increased tissue damage is observed in MKA females. 
Insets show higher magnification. 
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Table 3.2. Morphometric analysis of pancreatic tissue 60 days after activation of 
KRASG12D and loss of Atrx 
 
 
 
 
 
 
 
 Mist1creERT/+ Mist1creERT/+AtrxflΔ18 Mist1creERT/+ 
LSL-KRASG12D 
Mist1creERT/+LSL-
KRASG12DAtrxflΔ18 
Male 
(8) 
Female 
(5) 
Male  
(8) 
Female 
(5) 
Male 
(7) 
Female 
(10) 
Male 
(10) 
Female 
(6) 
Fibrosis 0 0 0 0 1 0.7 0 1.83 
Inflammation 0 0 0.14 0.33 1 1 0.2 2.17 
ADM 0 0.2 0 0 1.57 1.5 0.4 3 
Total 0±0 0.2±0.2 0.14±0.14 0.33±0.21 3.57±1.8 3.2±1.4 0.6±0.27 7±1.57 
(#) – indicates n value; see methodology for scoring. Histopathological assessment of pancreatic damage, as 
indicated by three factors; fibrosis, inflammation and the presence of ADM. Scores are represented on a grading 
scale from 0 – 4. There are increased levels of pancreatic damage in female Mist1creERT/+LSL-KRASG12DAtrxflΔ18 mice 
compared to other groups. 	
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Trichrome staining for fibrosis indicated the increased fibrotic areas in female MKA 
pancreatic tissue (Figure 3.10A; Supplementary Figure S3), while Alcian blue staining, 
which is characteristic of metaplastic lesions in this tissue, confirmed the presence of 
PanIN lesions (Figure 3.10A). The total number of lesions (ranging from ADM to 
PanIN2) was quantified within each group, and demonstrated a significant increase in the 
number of lesions within female MKA mice (Figure 3.10C), although quantification of 
total area of damage (expressed as a percentage of total tissue area) was not significant 
(Figure 3.10B). 
 
To determine the progression of PanIN formation within acinar tissue, Mist1creERT/+LSL-
KRASG12D and MKA mice were assessed for the presence of each lesion type (ranging 
from ADM to PanIN2); the percentage of pancreatic lobules containing at least one 
instance of each lesion type was quantified (Representative images of each in 
Supplemental Figure S5). Mist1creERT/+LSL-KRASG12D and MKA mice both exhibited 
ADM, however the incidence of PanIN1 was increased 2.5-fold in female MKA mice 
(Figure 3.10D). Furthermore, increased instances of PanIN2 were observed within 
female MKA mice (Figure 3.10D). These results demonstrated that Atrx loss increased 
sensitivity to KRASG12D and promoted increased damage, characteristic of chronic 
pancreatitis, and PanIN lesion formation, within a relatively short two-month time period. 
Furthermore, it appeared that damage was exclusive to the female MKA mice.  
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Figure 3.10. Increased pancreatic damage and progression in PanIN lesions were 
evident in female MKA mice. (A) Representative images of Alcian blue stain or 
Trichrome stain (indicator of fibrosis) confirms duct metaplasia (open arrow) and fibrosis 
(closed arrow) in areas of damage within female MKA mice. (B) Quantification of total 
lesion area (relative to total area of acinar tissue), and (C) total number of lesions within 
each group (* denotes p<0.05). Bars represent mean % of damage ± standard error. 
Mist1creERT/+AtrxflΔ18 are denoted as AtrxflΔ18, and Mist1creERT/+LSL-KRASG12D mice are 
denoted as LSL-KRASG12D. Female MKA mice demonstrate increased number of lesions, 
as well as a trend towards increased area of pancreatic damage. (D) Average percentage 
of lobules containing at least one instance of ADM to PanIN 2. Mist1creERT/+LSL-
KRASG12D mice are denoted as LSL-KRASG12D. Results demonstrate female MKA mice 
show increased levels of PanIN 1 and 2 lesions.  
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Similar to the recurrent pancreatic injury model, examination of SOX9 staining revealed 
no significant differences between Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice, nor 
increased staining in Mist1creERT/+LSL-KRASG12D and male MKA mice (Figure 3.11A). 
However, female MKA mice showed increased staining for SOX9 in the nucleus (Figure 
3.12A, Figure 3.12A) that was widespread in both pancreatic lesions and acinar tissue 
adjacent to areas of damage, suggesting acinar cells with increased SOX9 may be primed 
to undergo the ADM process. Again, Western blot analyses revealed no differences in 
global SOX9 levels (Figure 3.12C). To confirm ADM, transcription factor PDX1 was 
assessed. PDX1 is a factor essential for pancreatic development with low levels of 
expression in mature acinar tissue, but upregulated in ADM and PanIN lesions (Roy et 
al., 2016). Increased PDX1 staining was observed in female MKA acinar tissue adjacent 
to areas of damage and in pancreatic lesions (Figure 3.12B, Figure 3.12B) compared to 
all other groups, suggesting upregulation of ADM factors occurs in acinar tissue prior to 
ADM.  
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Figure 3.11. Loss of ATRX alone does not alter SOX9 and PDX1 staining in acinar 
cells.  IHC for SOX9 (A) and PDX1 (B) in control (Mist1creERT/+) and mice lacking 
ATRX (Mist1creERT/+AtrxflΔ18) revealed no differences in staining in either gender. 
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Figure 3.12. Loss of ATRX combined with oncogenic KRAS lead to increased SOX9 
and PDX1 staining in acinar tissue only in female MKA mice. IHC for SOX9 (A) and 
PDX1 (B) in Mist1creERT/+LSL-KRASG12D (denoted as LSL-KRASG12D) and MKA mice of 
both genders revealed increased acinar cell staining specifically in female MKA mice 
(black arrows), and expression in putative ADM (open arrows). (C) Representative 
western blot analyses for SOX9 reveals no significant differences between groups. Total 
ERK1/2 (tERK1/2) was used as a loading control. 
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3.3 Acinar cells with loss of ATRX contribute to KRAS-
mediated pancreatic lesion formation  
 
To determine if loss of ATRX alters proliferation in acinar cells, a largely post-mitotic 
tissue, IHC for Ki67 was performed (Figure 3.13A). Compared to mice with ATRX 
expression, Mist1creERT/+AtrxflΔ18 mice demonstrated increased numbers of Ki67+ acinar 
cells, indicating an increased number of cells are undergoing active cell division (Figure 
3.13). These results suggest that loss of ATRX results in increased acinar cell 
proliferation.   
 
To further examine the manner in which ATRX loss may influence the development of 
pancreatic damage, ATRX staining was assessed within pancreatic lesions of 
Mist1creERT/+LSL-KRASG12D and MKA mice of both genders. Lesions present within 
Mist1creERT/+LSL-KRASG12D mice were mostly ATRX positive (Figure 3.14A, B). Female 
Mist1creERT/+LSL-KRASG12D mice heterozygous for ATRX expression (Mist1creERT/+LSL-
KRASG12DAtrxflΔ18/x) demonstrated 58±17% ATRX-positive lesions. However, lesions 
within male and female MKA mice exhibited 82±7% and 73±10% ATRX-negative 
lesions, respectively, with 17.5±7% and 27±10% ATRX-positive lesions (Figure 
3.14A,B). From these results, it appears that while PanIN formation can occur 
independently of ATRX expression, ADM and PanINs are forming mostly from ATRX-
negative cells. Interestingly, a pattern similar to the variable ATRX staining in female 
MKA mice is observed with Ki67 staining (Figure 3.14A).  
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Figure 3.13. Acinar cell proliferation is increased following the loss of ATRX. (A) 
Representative IHC indicated an increase in acinar-cell Ki67 staining in mice lacking 
ATRX, compared to control (Mist1creERT/+) mice (black arrow). (B) Quantification of 
Ki67+ acinar cells indicated a trend towards increased acinar cell proliferation with loss 
of ATRX in both genders, which did not increase in the presence of oncogenic KRAS. 
Mist1creERT/+AtrxflΔ18 are denoted as AtrxflΔ18, and Mist1creERT/+LSL-KRASG12D mice are 
denoted as LSL-KRASG12D. 
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Figure 3.14. Acinar cells with loss of ATRX contribute to KRAS-mediated 
pancreatic lesion formation. (A) IHC for Ki67 in Mist1creERT/+LSL-KRASG12D (denoted 
as LSL-KRASG12D) and MKA mice indicated positive Ki67 cells in male and female MKA 
mice (open arrows). ATRX expression was evident in PanINs in female Mist1creERT/+LSL-
KRASG12D mice (black arrow), while female MKA revealed both ATRX+ and ATRX- 
cells within the PanINs (* indicates lesion with some ATRX+ cells; ** indicates lesion 
with no ATRX+ cells), confirming cells with ATRX loss can contribute to ADM and 
PanIN lesions. (B) Quantification of lesions with ATRX+ or ATRX- cells in 
Mist1creERT/+, Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D and MKA 
mice. Bars represent mean % ± standard error. 
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Chapter 4  
4 Discussion 
 
4.1 Overall Findings 
 
This work defines a novel role for chromatin remodeler ATRX within the adult exocrine 
pancreas, utilizing a cre-loxP mouse model to inducibly ablate ATRX expression in 
pancreatic acinar cells. Loss of ATRX within acinar tissue does not produce 
morphological changes or impact short-term survival, indicating ATRX is not required 
for mature acinar cell viability. However, ATRX loss caused modest increases in DNA 
damage, proliferation and apoptosis, indicating mild injury may be induced in acinar 
tissue with loss of ATRX.  
 
When exposed to recurrent pancreatic injury, the loss of ATRX resulted in greater extent 
of pancreatic damage, demonstrating increased levels of fibrosis, inflammation and 
ADM. Furthermore, combination of ATRX loss with oncogenic KRAS activation 
produced extensive pancreatic damage indicative of chronic pancreatitis. Increased 
fibrosis and inflammation was observed, as well as the presence of PanIN lesions up to 
PanIN grade 2. Interestingly, this damage was exclusive to the female population of mice, 
suggesting a gender-specific effect of ATRX. Taken together, this work demonstrates 
that ATRX loss enhances the susceptibility of acinar tissue to pancreatic injury, either by 
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experimentally induced pancreatitis or oncogenic KRAS activation, through gender 
specific mechanisms. This pancreatic injury has the potential to progress into PDAC in 
females, and thus ATRX loss in humans may act in co-operation with KRAS to promote 
PDAC.   
 
4.2 General Discussion 
 
4.2.1 Role of ATRX in pancreatic injury  
 
Three days following recurrent cerulein-induced pancreatitis, mice lacking ATRX had 
increased pancreatic damage, with a fibrotic response, inflammatory cell infiltration and 
instances of ADM, which are not observed in the control mice. Differences in levels of 
circulating serum amylase were not observed between control and Mist1creERT/+ AtrxflΔ18 
mice, however this is not unexpected as mice were allowed to recover for three days prior 
to sacrifice.  There are at least two possible ways in which ATRX loss can lead to 
increased damage; either the loss of ATRX causes more extensive initial injury, or ATRX 
loss interferes with the regenerative process.  
 
If the former option is true, this suggests that the initial damage in Mist1creERT/+ AtrxflΔ18 
mice requires a longer recovery time for complete regeneration to occur, explaining the 
difference in levels of damage between control and Mist1creERT/+ AtrxflΔ18 mice, 3 days 
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post-injury. Previous work in our lab using an acute pancreatitis protocol indicated 
relatively similar amounts of damage in control and Mist1creERT/+ AtrxflΔ18 mice, 
immediately following injury. However, repeated episodes of acute pancreatitis 
(recurrent pancreatitis) in this study could amplify the amount of initial damage observed 
with ATRX loss. In support of this, the downregulation of Mist1 gene expression 
observed in mice lacking ATRX suggests an initial susceptibility to pancreatic injury, as 
loss of Mist1 prior to injury has been shown to increase necrosis and tissue damage in 
acute cerulein-induced pancreatitis (Kowalik et al., 2007). To determine if ATRX loss 
does result in worse initial damage after recurrent injury, assessment of pancreatic tissue 
immediately following injury would allow for comparison between initial damage in 
control and Mist1creERT/+AtrxflΔ18 mice.  
 
Conversely, it is possible that the loss of ATRX delays or impairs the regenerative 
process following injury. Previous studies have identified roles for chromatin remodeling 
proteins in regeneration after pancreatitis, including EZH2 and BMI1, members of the 
polycomb repressive complex family of proteins (Fukuda et al., 2012; Mallen-St. Clair et 
al., 2012). In both studies, acinar regeneration was compromised with loss of the 
chromatin remodeling protein, due to decreased proliferation. In this study, ATRX loss in 
non-injured acinar tissue increased DNA damage (indicated by positive gH2AX staining) 
and acinar cell apoptosis in a small subset of acinar cells, potentially inducing these 
effects in the relatively few acinar cells that are actively undergoing cell division. This 
would be consistent with previous roles of ATRX in mitotically active tissue, where 
ATRX has been shown to maintain genomic stability and regulate cell cycle processes 
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(Ritchie et al., 2008; Watson et al., 2013; Clynes et al., 2014; Huh et al., 2012). It is 
possible that these defects become more wide-spread once injury is induced, and 
increased DNA damage and/or replicative defects may provide a barrier to acinar tissue 
regeneration. Interestingly, assessment of apoptosis and proliferation markers in cerulein-
treated mice revealed variable results, suggesting that this is not the primary mechanism 
through which ATRX loss promotes damage.  
 
Another possible mechanism of pancreatic damage could include increased inflammation 
with loss of ATRX, preventing proper regeneration from occurring. A typical 
inflammatory response in pancreatitis includes the infiltration of leukocytes and 
macrophages, causing secretion of inflammatory cytokine tumour necrosis factor a 
(TNFa) and interleukin-6 (IL-6), as well as other factors that promote pancreatic stellate 
cell activation and subsequent fibrosis (Sendler et al., 2013; Shimada et al., 2002; Treiber 
et al., 2011; Mews et al., 2002). Assessment and/or inhibition of these cytokines and their 
downstream pathways (NF-kB, JAK/STAT signaling) in this pancreatitis model could 
further characterize a relationship between ATRX loss and inflammation. Future 
experiments could also include assessment of additional long term time points, 1- 2 
weeks following injury, to determine if ATRX loss has delayed or fully blocked 
regeneration from occurring. 
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4.2.2 SOX9 Regulation  
 
Following pancreatic injury or KRAS activation, mice lacking ATRX exhibit increased 
instances of ADM, which contain obvious nuclear staining for SOX9, a progenitor cell 
marker expressed in ADM and early PanIN lesions. This is expected, as SOX9 
expression as a driving factor in ADM has been well-established previously (Kopp et al., 
2012; Prevot et al., 2013). Further, SOX9 staining was also observed in acinar tissue 
surrounding ADM, suggesting SOX9 precedes the morphological change from acinar cell 
to ADM. Interestingly, Western blot analyses of SOX9 did not demonstrate differential 
SOX9 levels, contradicting the immunohistochemical analyses of SOX9. This finding is 
aligned with work from our collaborating lab of Dr. Arthur Brown, in which they 
observed no changes in SOX9 mRNA levels, but altered IHC staining of SOX9. There 
are a couple potential reasons for this difference: post-translational modification of SOX9 
or factors influencing antibody binding and/or specificity. Transcriptional regulation of 
SOX9 expression is downstream of several signaling pathways, including NF-kB (Sun et 
al., 2013), Wnt/b catenin (Larsimont et al., 2015) and MAPK signaling (Ling et al., 
2011). However, modifications of the SOX9 protein have also been demonstrated, 
including phosphorylation (Huang et al., 2000) and acetylation which prevented nuclear 
translocation of the SOX9 (Bar Oz et al., 2016). It is possible that post-translational 
modification of SOX9 alters the nuclear localization of this protein, leading to changes in 
staining intensity in IHC. Alternatively, these modifications or other alterations to SOX9 
protein conformation could prevent antibody binding in immunohistochemistry, which 
would not be an obstacle in the denatured environment of Western blot analyses.  
 90 
4.2.3 Role of ATRX in combination with oncogenic KRAS activation  
 
My results indicate that Atrx deletion or oncogenic KRAS mutation alone in adult acinar 
tissue does not lead increased pancreatic damage. In accordance with previous literature 
(Grippo et al., 2003; Guerra et al., 2007), activating KRAS mutations required an 
additional acquired mutation, in this case ATRX loss, to promote pancreatic damage. 
Interestingly, this study demonstrates a gender specific pancreatic phenotype, in which 
ATRX loss/KRAS activation leads to extensive damage within the female cohort. Similar 
to the recurrent pancreatic injury model, increased infiltration of inflammatory cells and 
extensive fibrosis are present, consistent with a chronic pancreatitis phenotype. 
Furthermore, instances of ADM and more progressive PanIN lesions were present in the 
tissue. The presence of PanIN lesions indicates the potential for progression to PDAC, 
although full-blown pancreatic cancer was not observed in this study.  
 
However, a study by Guerra et al., 2007 demonstrated that inducing KRAS activation in 
adult mice, when combined with chronic pancreatitis, produced invasive PDA within 5 
months of oncogenic KRAS activation. The pancreatic injury observed in the female 
MKA mice indicates the presence of chronic pancreatitis. Due the presence of active 
KRAS in this mouse model, it is likely that extending the length of this experiment past 
two months could reveal the presence of PDAC in MKA female mice.  
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Studies of ATRX mutation in other cancer types (including pancreatic neuroendocrine 
tumours) demonstrate a strong correlation between loss of ATRX or its binding partner 
DAXX and upregulation of the alternative lengthening of telomeres (ALT) pathway 
(Lovejoy et al., 2010; Heaphy et al., 2011a). However, a study examining PDAC tumours 
(n=448) confirmed the absence of ALT in every case (Heaphy et al., 2011b). Further, 
PDAC is typically characterized by telomere attrition, with telomere shortening evident 
in all PanIN grades (van Heek et al., 2002). This strongly suggests that unlike other 
cancer types, loss of ATRX does not drive damage through an ALT phenotype. However, 
to rule out this possibility, assessment of telomere length in lesions of the female MKA 
mice could be performed.  
 
The exact mechanism through which ATRX loss can promote activity of oncogenic 
KRAS is unclear. A well characterized function of ATRX is mediating deposition of 
histone variant H3.3, in conjunction with binding partner DAXX (Drane et al., 2010; 
Lewis et al., 2010). Loss of ATRX, and subsequent alteration of H3.3 deposition, could 
influence chromatin structure and modify gene expression, leading to activation of 
oncogenic KRAS and/or downstream pathways which further potentiate KRAS activity. 
Pathways downstream of KRAS are diverse and regulate many different cellular 
processes, including proliferation and cell survival, which could promote pancreatic 
damage (Castellano and Downward, 2011; Crespo et al., 2000). Performing similar 
experiments with an inducible DAXX deletion could reveal if ATRX activity in this 
model is DAXX-dependent. Alternatively, ATRX could be functioning in a DAXX-
independent manner to influence gene expression, working in complex with other 
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proteins or complexes, including PRC2. Previous literature has confirmed interaction 
between ATRX and EZH2, a member of PRC2, leading to altered gene expression 
(Cardoso et al., 1998; Sarma et al., 2014). Whole genome analysis of mRNA expression, 
using RNA-sequencing of pancreatic tissue in mice, at a time point prior to the 
development of damage, could demonstrate changes in gene expression and help to 
pinpoint specific genes of interest.  
 
4.2.4 Gender Specificity of Pancreatic Damage in MKA mice 
 
The incidence of human PDAC between genders is relatively equal, with approximately 
the same number of cases occurring in males and females (Canadian Cancer Statistics, 
2016). However, it is possible that ATRX loss defines a unique subtype of PDAC, in 
which the female population is more susceptible. The gender-specific mechanism 
producing extensive pancreatic damage specifically in female MKA mice remains 
unclear. In this study, female mice heterozygous (AtrxflΔ18/ x) or homozygous (AtrxflΔ18/ 
flΔ18) for the mutant Atrx allele showed different results when combined with KRAS 
activation. In mice that are heterozygous for the mutant Atrx allele (AtrxflΔ18/ x), it is 
expected that approximately half of acinar cells will lose ATRX expression completely 
due to X-inactivation of the wild-type Atrx allele. However, these mice did not 
demonstrate increased damage with KRAS mutation, and were subsequently grouped 
together with mice containing two wild-type Atrx alleles (Atrxx/ x) during analysis. These 
results suggest that complete loss of ATRX in acinar tissue is required to produce 
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pancreatic damage, possibly due to skewed X-inactivation of the chromosome containing 
the mutant Atrx allele. Interestingly, the male MKA mice appear to have the opposite 
effect from their female counterparts, showing a protective effect and decreased damage 
with ATRX loss/KRAS activation.  
 
There are three potential mechanisms through which MKA mice may have gender-
specific differences in damage. First, hormonal factors could be considered to play a role. 
Sex hormone receptors, including estrogen receptors (ER) have been known to play a role 
in the progression of other cancers such as breast and colon (Nussler et al., 2008; Perou et 
al., 2000). Further, specific rare types of pancreatic neoplasms, including papillary and 
mucinous cystic neoplasms, have a higher incidence in females and have been linked to 
ER upregulation (Kosumi et al., 2015; Satake et al., 2006). Estrogen receptors 
(specifically ERa) can be activated by MAPK signaling, and can mediate regulation of 
cellular growth and survival (Kato et al., 1995; Thomas and Gustafsson, 2011). It is 
possible that increased KRAS activity, due to ATRX loss, in female MKA mice could 
induce ER upregulation and growth factor signaling in acinar tissue. The level of 
expression of estrogen receptors, or other sex hormone receptors (progesterone) within 
pancreatic tissue of MKA mice could be assessed using immunohistochemical staining to 
test this theory.  
 
Second, it is possible that aberrant gene expression from the silenced X-chromosome 
may occur with loss of ATRX. ATRX co-operates with polycomb repressive complex 2 
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(PRC2) to mediate gene silencing, including inactivation of the X chromosome (XCI) 
(Cardoso et al., 1998; Sarma et al., 2014). Loss of XCI has been demonstrated in other 
cancer types including ovarian and breast cancer (Chaligne et al., 2015), and genes 
located on the X chromosome have been implicated in cancer, including cancer/testis 
antigen and the Wtx gene (Kang et al., 2015; Rivera et al., 2007). It is possible that re-
activation of the X-chromosome with loss of ATRX could greatly increase the expression 
of X-linked genes, an event which would be specific to female cohort of MKA mice. To 
confirm this theory, RNA-sequencing of acinar tissue would allow for complete 
assessment of changes in X-linked gene expression.  
 
Finally, gender-specific mechanisms could be explained by a difference in inflammatory 
response between male and female mice. It is possible that female mice with ATRX loss 
are more susceptible to factors promoting inflammation, such as pancreatic injury. In 
support of this theory, female Mist1creERT/+ AtrxflΔ18 mice that underwent recurrent 
pancreatic injury showed increased inflammation in comparison to their male 
counterparts, resulting in higher levels of damage. Accordingly, increased inflammation 
in female MKA mice could lead to increased damage, promoting widespread lesion 
formation. High levels of KRAS activity can induce senescence as a tumour suppressive 
mechanism, termed oncogene-induced senescence (OIS) (Collado et al., 2005; Serrano et 
al., 1997). Interestingly, Guerra et al., 2011 demonstrated that the presence of pancreatic 
inflammation could overcome this senescent mechanism, contributing to the progression 
of PDAC. In this model, an increased inflammatory response in female MKA mice could 
amplify oncogenic KRAS and activation of downstream pathways, including MAPK and 
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PI3K-PDK1-Akt signaling, leading to increased cell survival and proliferation. 
Accordingly, increased KRASG12D activity by inflammatory cytokines, including NF-kB 
and IL-6, has been demonstrated previously (Daniluk et al., 2012; Baumgart et al., 2014; 
Lesina et al., 2011). The presence of an inflammatory response in the female MKA mice, 
which is not observed in male MKA mice, could overcome OIS specifically within the 
female cohort of mice, leading to increased damage. Assessment of senescent markers 
within these mice could confirm this theory.  
 
In summary, based on the results shown in this study, it is clear that ATRX loss can 
enhance pancreatic injury or susceptibility to KRAS-mediated pancreatic damage. 
Oncogenic KRASG12D mutation places the KRAS protein in a primed state, leading to 
high levels of KRAS activity upon stimulation. It is proposed that ATRX loss is able to 
promote high levels of KRAS activity, which may be attenuated in male MKA mice 
through oncogene-induced senescence (OIS) leading to decreased damage (Figure 4.1). 
Potential gender specific factors within female MKA mice (including hormonal factors, X 
chromosome re-activation, or increased inflammation) may provide an additional driving 
factor for KRAS activity and pancreatic damage, leading to a female-specific phenotype.  
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Figure 4.1. Proposed model for the loss of ATRX contributing to KRASG12D-
mediated PanIN formation. In this model, KRASG12D makes acinar cells susceptible to 
further stimulation (including injury or further mutation). Loss of ATRX is sufficient to 
stimulate high levels of KRAS activity, triggering oncogene-induced senescence (OIS) in 
male mice and protecting acinar tissue from oncogenic transformation. In female mice, 
additional gender-specific factors (possibly inflammatory or hormonal differences) allow 
acinar cells to overcome OIS, leading to acinar-to-ductal metaplasia (ADM) and PanIN 
formation. 
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4.3 Limitations & Future Directions  
 
This study defines a novel role for ATRX within the pancreas. However, there are 
limitations to the experimental design which must be considered. The Mist1 gene, used to 
drive cre-mediated recombination in this model, is specific to serous exocrine cells, and 
thus provided an acinar-specific deletion of Atrx/activation of KRAS within the pancreas. 
However, since MIST1 is expressed in other tissue types (including stomach and salivary 
gland), Atrx deletion and expression of oncogenic KRAS also occurred in these tissues. 
Therefore, there were non-pancreatic effects including the formation of tumours in the 
stomach and mouth of these mice. This effectively limited the timeframe of this study, 
and prevented the observation of pancreatic phenotype at potential later time points, 
where PDAC is most likely to develop.  Use of a different acinar-specific cre-driver (e.g. 
Ptf1a) in future experiments would allow for longer-term studies. Furthermore, the dose 
of pancreatitis used in the recurrent pancreatitis experiments was suboptimal (75 µg/ml), 
compared to other studies which used similar cerulein administration protocols (Halbrook 
et al., 2017) and showed more extensive damage in their mice. Use of a higher cerulein 
dose in this experiment may have revealed greater differences between control mice and 
mice lacking ATRX. 
 
Moving forward, studies to further investigate the cooperation between ATRX loss and 
KRAS activation will help to elucidate the exact mechanism through which this 
phenotype occurs. Both cell-autonomous (dependent on ATRX loss within the cell) and 
 98 
non-cell autonomous (e.g. inflammation) mechanisms should be considered. Using cell 
culture techniques, acinar cells from male and female mice lacking ATRX could be 
isolated and plated in collagen matrix. The propensity of these cells to undergo 
conversion to a duct-like state in culture can be assessed, to determine if there is an 
inherent susceptibility to ADM in cells lacking ATRX (cell-autonomous event). Analysis 
of gene expression using RNA-sequencing could identify the influence of ATRX loss on 
gene expression, and potential pathways through which it may amplify KRAS activity. 
To investigate possible non-cell autonomous factors, including inflammation, anti-
inflammatory treatments could be administered in these models of pancreatic injury and 
KRAS-induced pancreatic damage. This would indicate the potential importance of 
inflammation in mediating the phenotypes observed in this study.  
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Chapter 6  
6  Appendices 
 
Supplemental Table S1. Histology grading criteria 
 
Acinar-to-ductal metaplasia (ADM)  
(based on worst pancreatic lobule) 
Fibrosis  
(based on Trichrome Stain) 
 
0 
 
None present 
 
0 
 
None present 
1 >10% of lobule 1 <5% of tissue area 
2 10-30% of lobule 2 5-10% of tissue area 
3 30-50% of lobule 3 10-20% of tissue area 
4 >50% of lobule  4 >20% of tissue area 
Inflammation 
 
0 
 
None present 
1 Focal – small, contained areas 
2 Mild – small, slightly diffuse areas 
3 Moderate – diffuse areas 
4 Severe – diffuse areas, significant presence throughout the tissue 
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Supplemental Figure S1. Representative images of histological grading scale. 
Representative histological images for each possible score (0-4) on the histological 
grading scale utilized for recurrent pancreatitis and oncogenic KRAS models (see Table 
3.1, 3.2). Three factors were assessed; inflammation, fibrosis (based on Trichrome stain), 
and acinar-to-ductal metaplasia (ADM). 
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Supplemental Figure S2. Increased gH2AX and TUNEL staining, 60 days following 
loss of ATRX. Representative immunofluorescence indicates an increased number of 
acinar cells positive for gH2AX and TUNEL staining (white arrows) in 
Mist1creERT/+AtrxflΔ18, compared to control mice.  
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Supplemental Figure S3. Minor morphological differences visible in pancreatic 
tissue, 60 days following Atrx deletion and/or oncogenic KRAS activation. (A) 
Representative images of pancreas in situ in control, Mist1creERT/+AtrxflΔ18, 
Mist1creERT/+LSL-KRASG12D and MKA mice (outlined by the dotted line). Edema is visible 
in female MKA mice, as well as an enlarged spleen (indicated by white arrow). 
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Supplemental Figure S4. Increased fibrosis in MKA mice compared to 
Mist1creERT/+LSL-KRASG12D mice. (A) Masson’s Trichrome stain in control and 
Mist1creERT/+AtrxflΔ18 saline or cerulein-treated mice, three days following cessation of 
CIP treatment. (B) Trichrome stain in control, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-
KRASG12D mice, 60 days following tamoxifen gavage (blue indicates fibrosis, indicated 
by black arrow). 
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Supplemental Figure S5. PanIN lesions progress to PanIN2 in MKA female mice. 
Representative H&E images of each grade of pancreatic lesion, ranging from ADM – 
PanIN 2, evident in the acinar tissue of MKA female mice (black arrows). 
50 μm
ADM PANIN1 PANIN2
 145 
Curriculum Vitae 
 
Name:		 Claire	Young	
	
Post-secondary		 University	of	Western	Ontario	
Education	and		 London,	Ontario,	Canada	
Degrees:		 	 2011-2015	B.Msc.	Honours	Specialization	in	Physiology	
	
University	of	Western	Ontario	
London,	Ontario,	Canada	
2015-2017	M.Sc.	Physiology	&	Pharmacology	
	
Honours	and		 	 Paediatric	Summer	Studentship	
Awards:		 	 2014	
	
Hugh	B.	Anderson	Award	in	Physiology	
2015	
	
Paediatric	Graduate	Scholarship	
2015-2016	
	
CIHR	Canada	Graduate	Scholarship	
2016-2017	
	
	
Related	Work			 Teaching	Assistant,	Physiology	3130	
Experience		 	 University	of	Western	Ontario	
2015-2016,	2016-2017	
	
	
Conferences	 	 Keystone	Symposium:	Epigenetics	in	Human	Disease	(Poster)	
	 	 	 Seattle,	WA,	USA	(2017)	
	
	 	 	 American	Pancreatic	Association	Annual	Meeting	(Poster)	
	 	 	 San	Diego,	CA,	USA	(2016),	Boston,	MA,	USA	(2017)	
	
	
Publications:	 	 	
Fazio,	E.F.,	Young,	C.C.	et	al.,	(2017).	Activating	Transcription	Factor	3	is	a	key	
transcriptional	regulator	during	exocrine	pancreatic	injury.	Mol	Biol	Cell.	Accepted,	
pending	revision.		
